Complete trial list · Long COVID

All Long COVID clinical trials

341 interventional trials on ClinicalTrials.gov, all statuses · updated October 2026

Last updated 07 October 2026 from ClinicalTrials.gov. Trial statuses are refreshed automatically; check the registry record for the latest status and contact details.

53 recruiting25 not yet recruiting3 enrolling by invitation26 active, not recruiting150 completed3 suspended10 terminated14 withdrawn57 unknown status

Every interventional study for Long COVID / post-acute sequelae of SARS-CoV-2 (PASC) in our ClinicalTrials.gov extract, regardless of status. Use this page to answer "has X been trialled in Long COVID?": search the page (Ctrl/Cmd-F) for a drug or intervention name, or browse the by-agent index.

Trials are grouped by status. Completed, terminated and withdrawn studies are included because they are often the most informative: a terminated trial may indicate futility, safety concerns or simply funding problems, so always read the record. Only trials currently open to enrolment are shown on the recruiting page.

Status badges: green = recruiting, blue = not yet recruiting, purple = enrolling by invitation, orange = active but closed to enrolment, grey = completed, red = terminated / withdrawn / suspended. "Unknown status" means the sponsor has not updated the record for more than two years past its expected completion date.
⚠️
Not medical advice. This page is an automatically compiled index of entries on ClinicalTrials.gov. Listing here is not an endorsement of any trial, sponsor or treatment, and trial status can change between our refreshes. Always confirm details on ClinicalTrials.gov and discuss participation with your own clinician.

Recruiting (53)

RecruitingPhase not applicable NCT07661862
Sponsor: University of Tasmania (Academic / non-profit / other)
Intervention(s): Perceive-Outreach Disease Management Program
Start: Apr 2026  |  Primary completion: Apr 2029  |  Enrollment: 577 (estimated)
Record last updated: Oct 2026

Some people who had COVID-19 continue to have symptoms for weeks, months, or even years after their infection. This is often called "Long COVID" or Post-Acute Sequelae of SARS-CoV-2 (PASC). For some people, Long COVID can affect the heart and lungs, making it harder to exercise or carry out daily activities.

View on ClinicalTrials.gov ↗
RecruitingPhase 3 NCT06928272
Sponsor: Douglas D. Fraser (Academic / non-profit / other)
Intervention(s): Pirfenidone, Upadacitinib
Start: Sep 2025  |  Primary completion: Dec 2026  |  Enrollment: 348 (estimated)
Record last updated: Oct 2026

The Long-Covid (LC)-Revitalize clinical study is testing repurposed drug treatments for Long Covid, involving adult participants from Brazil, Canada, Italy, South Africa, Uganda, the United States, and Zambia. To qualify, participants must have had Covid-19 and experienced Long Covid symptoms for at least three months.

View on ClinicalTrials.gov ↗
RecruitingPhase 2 NCT07021794
Sponsor: Nancy Klimas (Academic / non-profit / other)
Intervention(s): Sipavibart
Start: Jul 2025  |  Primary completion: Sep 2027  |  Enrollment: 100 (estimated)
Record last updated: Sep 2026

This placebo-controlled, randomized, blinded, two-arm phase II study will test the safety and potential efficacy of the targeted mAb, Sipavibart (formerly AZD3152) in patients with Long COVID.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT06928116
Sponsor: University of Nebraska (Academic / non-profit / other)
Intervention(s): Heat Therapy, Walking
Start: Jan 2025  |  Primary completion: Aug 2028  |  Enrollment: 99 (estimated)
Record last updated: Sep 2026

Post-acute sequelae of SARS-CoV-2 infection (PASC) is becoming a major risk factor for chronic diseases, with older adults and those with underlying health conditions at risk of developing persistent mobility limitations and disabilities. Although exercise intervention is a common strategy to restore functional capacity, it may not be feasible or enticing to many people with PASC.

View on ClinicalTrials.gov ↗
RecruitingPhase 3 NCT06631287
Sponsor: Wes Ely (Academic / non-profit / other)
Intervention(s): Baricitinib
Start: Oct 2024  |  Primary completion: Nov 2026  |  Enrollment: 550 (estimated)
Record last updated: Sep 2026

The overarching goal of this study is to determine if baricitinib, as compared to placebo, will improve neurocognitive function, along with measures of physical function, quality of life, post-exertional malaise, effect of breathlessness on daily activities, post-COVID-19 symptom burden, and biomarkers of inflammation and viral measures, in participants with Long COVID.

View on ClinicalTrials.gov ↗
RecruitingPhase 2 NCT07123727
Sponsor: ImmunityBio, Inc. (Industry)
Intervention(s): Anktiva
Start: Sep 2025  |  Primary completion: Mar 2027  |  Enrollment: 40 (estimated)
Record last updated: Sep 2026

This study will examine the safety and effectiveness of Anktiva in treating patients with Long COVID-19 which is defined as persistent symptoms of a COVID-19 infection that remain after the infection is over.

View on ClinicalTrials.gov ↗
RecruitingPhase 2 NCT06721949
Sponsor: University of Alberta (Academic / non-profit / other)
Intervention(s): Taurine
Start: Nov 2025  |  Primary completion: Feb 2028  |  Enrollment: 300 (estimated)
Record last updated: Sep 2026

The COVID-19 pandemic has swept across the globe, affecting millions of individuals with varying degrees of severity. While many individuals recover from the acute phase of the infection, a significant proportion continue to experience persistent and debilitating symptoms long after the initial SARS-CoV-2 infection.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT05851859
Sponsor: Centre Hospitalier Universitaire de la Réunion (Academic / non-profit / other)
Intervention(s): Cardiac Coherence
Start: May 2025  |  Primary completion: Nov 2026  |  Enrollment: 200 (estimated)
Record last updated: Sep 2026

Despite the controversy, on October 6, 2021, the World Health Organization (WHO) recognized Long Coronavirus disease (COVID) by officially defining it: " symptoms appeared 3 months after the onset of the primary infection by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), persisting for at least 2 months and which cannot be explained by any other condition ".

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT07140094
Sponsor: Columbia University (Academic / non-profit / other)
Intervention(s): Structured Mindfulness Intervention
Start: May 2024  |  Primary completion: May 2027  |  Enrollment: 400 (estimated)
Record last updated: Aug 2026

This research is being done to study a mindfulness intervention among people who have symptoms of Post-Acute Sequelae of SARS-CoV-2 infection (PASC), also known as Long COVID. Mindfulness is defined as paying attention to the present moment with non-judgment and acceptance.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT07726082
Sponsor: University Hospital, Basel, Switzerland (Academic / non-profit / other)
Intervention(s): Micro-Choice-Based Intervention
Start: Aug 2026  |  Primary completion: Aug 2027  |  Enrollment: 24 (estimated)
Record last updated: Aug 2026

This proof-of-concept study aims to evaluate the feasibility, acceptability, and potential benefits of a novel multimodal approach: the micro-choice-based intervention.

View on ClinicalTrials.gov ↗
RecruitingPhase 2 NCT06940609
Sponsor: University of New Mexico (Academic / non-profit / other)
Intervention(s): Accelerated Intermittent Theta Burst Stimulation
Start: Jul 2025  |  Primary completion: Jun 2029  |  Enrollment: 60 (estimated)
Record last updated: Jul 2026

The goal of this clinical trial is to test whether a type of rapid outpatient brain stimulation that uses magnetic fields, called accelerated intermittent theta burst stimulation (iTBS), can treat symptoms such as brain fog, depression, and anxiety in patients with Long COVID. The main questions it aims to answer are: * Is iTBS effective and feasible for reducing Long COVID symptoms?

View on ClinicalTrials.gov ↗
RecruitingPhase 1 NCT07224490
Sponsor: Stephanie B. Seminara, MD (Academic / non-profit / other)
Intervention(s): Kisspeptin 112-121
Start: Mar 2026  |  Primary completion: May 2030  |  Enrollment: 40 (estimated)
Record last updated: Jul 2026

The objective of this protocol is to use a case-control paradigm to compare the response to an intravenous administration of kisspeptin in individuals with and without post-covid-19 syndrome. The study subjects will receive a single bolus of kisspeptin.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT05977179
Sponsor: University of Maryland, Baltimore (Academic / non-profit / other)
Intervention(s): Dietary Intervention To Mitigate Post-Acute Covid-19 Syndrome
Start: May 2025  |  Primary completion: Jun 2028  |  Enrollment: 56 (estimated)
Record last updated: Jun 2026

The primary objective of this study is to conduct a 16-week randomized controlled trial aimed at investigating the effectiveness of the Whole-Diet Approach when following a healthy US-style diet rich in anti-inflammatory properties. The study will focus on evaluating its impact on reducing symptoms related to Post-Acute Sequelae of SARS-CoV-2 Infection (PACS) in adults aged 50 years and older.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT06142253
Sponsor: VA Office of Research and Development (US federal agency)
Intervention(s): Water+Ct
Start: Dec 2024  |  Primary completion: Dec 2026  |  Enrollment: 50 (estimated)
Record last updated: Jun 2026

This two-year study will evaluate the feasibility and safety of an exercise + cognitive training program to improve neurological symptoms of long-COVID. This is a two-phased trial: 1) an exercise phase and 2) a cognitive training phase. The exercise phase will be an aquatic based exercise program.

View on ClinicalTrials.gov ↗
RecruitingPhase 3 NCT07359482
Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (Academic / non-profit / other)
Intervention(s): Fluvoxamine
Start: Jun 2026  |  Primary completion: Dec 2027  |  Enrollment: 160 (estimated)
Record last updated: Jun 2026

Fatigue, cognitive problems, post-exertional malaise (PEM) and postural orthostatic tachycardia syndrome (POTS) are common and debilitating symptoms after COVID-19. The pathophysiology of post-COVID is not well understood and there is no established biomedical treatment. Treatment options for post-COVID are thus much needed.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT06614309
Sponsor: Mayo Clinic (Academic / non-profit / other)
Intervention(s): Acute Progressive Carbon Dioxide, Acute Intermittent Hypoxia, Training: Progressive Carbon Dioxide Ramping, Training: Intermittent Hypoxic Exposure
Start: Sep 2024  |  Primary completion: Dec 2026  |  Enrollment: 45 (estimated)
Record last updated: Jun 2026

This study aims to assess the effects of both acute and chronic exposures to hypoxia and hypercapnia in patients with Long COVID syndrome.

View on ClinicalTrials.gov ↗
RecruitingPhase 2 NCT07627815
Sponsor: ParagonClinicals Inc. (Industry)
Intervention(s): Paragon Novel Metabolic Regulator, Dietary And Lifestyle Recommendations
Start: May 2026  |  Primary completion: Aug 2026  |  Enrollment: 82 (estimated)
Record last updated: Jun 2026

This will be a six-week, randomized, parallel, two group, open-label design. Patients will be treated with Paragon Novel Metabolic Regulator (PNMR) + standard of care (SOC) or SOC alone for 6 weeks for the treatment of Long COVID. All patients will also be provided with with Dietary \& Lifestyle recommendations specifically designed to enhance immune system function and reduce viral proliferation.

View on ClinicalTrials.gov ↗
RecruitingEarly Phase 1 NCT07076862
Sponsor: University of California, Davis (Academic / non-profit / other)
Intervention(s): A.1 - [¹⁸F]F-Arag Pet/Ct, A.2 - [¹⁸F]F-Arag Pet/Ct, B.1 - [¹⁸F]F-Arag Pet/Ct, B.2 - [¹⁸F]F-Arag Pet/Ct
Start: Dec 2025  |  Primary completion: Dec 2028  |  Enrollment: 51 (estimated)
Record last updated: May 2026

This study uses total-body \[¹⁸F\]F-AraG PET/CT imaging to investigate immune activation and vascular changes in individuals with post-acute sequelae of SARS-CoV-2 infection (PASC), also known as Long COVID. Participants will undergo dynamic PET/CT imaging along with blood biomarker assessments and symptom evaluations.

View on ClinicalTrials.gov ↗
RecruitingPhase 3 NCT06960928
Sponsor: Icahn School of Medicine at Mount Sinai (Academic / non-profit / other)
Intervention(s): Sirolimus (low-dose)
Start: Apr 2025  |  Primary completion: Dec 2026  |  Enrollment: 80 (estimated)
Record last updated: May 2026

The study is conducted in New York, New York at The Cohen Center for Recovery from Complex Chronic Illness at Mount Sinai. This is an IND-exempt, off-label, multi-ascending, randomized, placebo-controlled clinical trial of sirolimus (also known as rapamycin) in adults with Long COVID. There are 2 arms: Sirolimus and Placebo.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT06871293
Sponsor: Fundación Cardioinfantil Instituto de Cardiología (Academic / non-profit / other)
Intervention(s): Functional And Cognitive Rehabilitation Strategy, Evidence-Based Informational Support
Start: Oct 2025  |  Primary completion: Dec 2026  |  Enrollment: 374 (estimated)
Record last updated: Apr 2026

This study aims to evaluate the impact of a functional and cognitive rehabilitation strategy compared to evidence-based informational messages, on functional capacity, cognitive abilities, quality of life, and disease progression in adults with chronic non-communicable diseases (NCDs) and Long Covid-19.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT06095297
Sponsor: University of Alabama at Birmingham (Academic / non-profit / other)
Intervention(s): Processing Speed Training, In-Lab Instrumental Activities Of Daily Living Training, In-Lab Brain Health Training, Transfer Package, Follow Up Phone Calls, Vocational Rehabilitation, Peer Mentoring, Reaction Time Training, Trans-Auricular Vagus Nerve Stimulation: High Intensity, Trans-Auricular Vagus Nerve Stimulation: Low Intensity
Start: Apr 2024  |  Primary completion: Dec 2026  |  Enrollment: 30 (estimated)
Record last updated: Apr 2026

This study will compare two approaches to cognitive rehabilitation in adults with long COVID with persistent, mild to moderate, cognitive impairment.

View on ClinicalTrials.gov ↗
RecruitingPhase 2 NCT05855369
Sponsor: Medical University of South Carolina (Academic / non-profit / other)
Intervention(s): Trigeminal Nerve Stimulation, Active Smell Training
Start: Oct 2023  |  Primary completion: May 2028  |  Enrollment: 145 (estimated)
Record last updated: Apr 2026

Persistent smell loss that can include diminished or distorted smell function is a common symptom of long COVID syndrome. There are limited treatment options for long COVID-related smell loss. This study aims to determine the efficacy of two at-home treatments, smell training and non-invasive trigeminal nerve stimulation.

View on ClinicalTrials.gov ↗
RecruitingPhase 2 NCT05764538
Sponsor: Chang Gung Memorial Hospital (Academic / non-profit / other)
Intervention(s): Daoib
Start: Feb 2023  |  Primary completion: Jun 2026  |  Enrollment: 40 (estimated)
Record last updated: Mar 2026

This is a 24-week open trial. We will enroll long-COVID patients with cognitive impairments. All patients will receive DAOIB for 24 weeks.

View on ClinicalTrials.gov ↗
RecruitingPhase 2 NCT06511063
Sponsor: Icahn School of Medicine at Mount Sinai (Academic / non-profit / other)
Intervention(s): Tenofovir Disoproxil/Emtricitabine, Selzentry
Start: Oct 2024  |  Primary completion: Nov 2026  |  Enrollment: 90 (estimated)
Record last updated: Mar 2026

The trial will test if two repurposed HIV antivirals can reduce symptom burden in adult participants with Long Covid compared to placebo. Viral infection and viral reactivation have been documented in Long Covid. Participants will be randomly allocated to receive antivirals, Truvada (tenofovir disoproxil/emtricitabine, TDF/FTC, Group 1) or Selzentry (Group 2), or a placebo (pill) (Group 3), taken daily for 90 days.

View on ClinicalTrials.gov ↗
RecruitingPhase 1 NCT06511050
Sponsor: Icahn School of Medicine at Mount Sinai (Academic / non-profit / other)
Intervention(s): Lumbrokinase
Start: Oct 2024  |  Primary completion: Dec 2026  |  Enrollment: 120 (estimated)
Record last updated: Mar 2026

This will be a pilot multi-arm clinical trial investigating the feasibility of Lumbrokinase (LK) as an intervention in three clinical cohorts: * Long Covid (LC) * Post-treatment Lyme disease syndrome (PTLDS) * Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT06452095
Sponsor: University Health Network, Toronto (Academic / non-profit / other)
Start: Jan 2026  |  Primary completion: Dec 2029  |  Enrollment: 120 (estimated)
Record last updated: Feb 2026

The RECLAIM study platform will be used to explore whether the use of Hyperbaric Oxygen therapy (HBOT) improves the symptoms of post covid cognitive dysfunction. Hyperbaric oxygen therapy is a well-established medical treatment. HBOT promotes healing by delivering a high concentration of oxygen into the body.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT06045338
Sponsor: Beth Israel Deaconess Medical Center (Academic / non-profit / other)
Intervention(s): Mind Body Intervention #1
Start: Nov 2023  |  Primary completion: Sep 2026  |  Enrollment: 180 (estimated)
Record last updated: Feb 2026

The goal of this study is to determine if a mind-body intervention can help people suffering from symptoms associated with Long COVID. The study is a randomized trial examining the effectiveness of a mind body intervention in reducing somatic symptoms from Long COVID in participants as compared to usual care and an active control (second mind body intervention).

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT07374562
Sponsor: Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec (Academic / non-profit / other)
Intervention(s): Stellate Ganglion Block
Start: Feb 2026  |  Primary completion: Feb 2027  |  Enrollment: 40 (estimated)
Record last updated: Feb 2026

This single-center, randomized, controlled, single-blind clinical trial evaluates whether a stellate ganglion block (SGB) using bupivacaine can improve persistent symptoms in adults with long COVID. Participants are assigned in a 1:1 ratio to receive either an ultrasound-guided right-sided SGB or a placebo saline injection delivered to the sternocleidomastoid muscle.

View on ClinicalTrials.gov ↗
RecruitingPhase 4 NCT06980636
Sponsor: Beijing University of Chinese Medicine (Academic / non-profit / other)
Intervention(s): Shengmai Liquid
Start: Dec 2025  |  Primary completion: Oct 2026  |  Enrollment: 100 (estimated)
Record last updated: Feb 2026

The goal of this clinical trial is to learn if Shengmai liquid works to treat Long Covid fatigue. It will also learn about the safety of Shengmai liquid.

View on ClinicalTrials.gov ↗
RecruitingPhase 2 NCT07189936
Sponsor: Vanderbilt University Medical Center (Academic / non-profit / other)
Intervention(s): To Measure Levels Of Circulating Monocyte/ T Cell Doublets At Baseline, To Measure Levels Of Circulating Monocyte/ T Cell Doublets After 28 Days Of 2 Hoba Treatment, To Measure Splanchnic Venous Capacitance After 28 Days Of Treatment With 2Hoba, To Measure Orthostatic Tachycardia After 28 Days Of Treatment With 2Hoba
Start: Dec 2025  |  Primary completion: Jun 2028  |  Enrollment: 50 (estimated)
Record last updated: Jan 2026

Long COVID is defined by a range of symptoms affecting multiple organs that persist for more than three months following an acute SARS-CoV-2 infection. Approximately 7% of individuals who recover from SARS-Cov-2 infection develop Long COVID.

View on ClinicalTrials.gov ↗
RecruitingPhase 2 NCT05926505
Sponsor: Hellenic Institute for the Study of Sepsis (Academic / non-profit / other)
Intervention(s): Anakinra 149 Mg/Ml Prefilled Syringe [Kineret]
Start: Sep 2023  |  Primary completion: Mar 2028  |  Enrollment: 182 (estimated)
Record last updated: Jan 2026

The PRECISION is a proof-of-concept, phase II randomized clinical trial aiming to evaluate the efficacy and safety of anakinra in patients with Post-Acute COVID Syndrome (PACS) of the pro-inflammatory respiratory phenotype. Improvement is measured by a composite endpoint, namely, the "Score of PACS progression reversal".

View on ClinicalTrials.gov ↗
RecruitingPhase 2 NCT07316127
Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (Academic / non-profit / other)
Intervention(s): Immunoadsorption
Start: Jan 2026  |  Primary completion: Dec 2027  |  Enrollment: 70 (estimated)
Record last updated: Jan 2026

Some people continue to have serious symptoms long after COVID-19, such as extreme fatigue and feeling worse after activity. In some patients, this may happen because the immune system is attacking the body by mistake. This study will test a treatment called immunoadsorption, which filters the blood to remove harmful antibodies.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT07278206
Sponsor: Amsterdam UMC, location VUmc (Academic / non-profit / other)
Intervention(s): Repetitive Transcranial Magnetic Stimulation
Start: Nov 2025  |  Primary completion: Nov 2028  |  Enrollment: 66 (estimated)
Record last updated: Dec 2025

Cognitive problems and severe fatigue are two frequently occurring symptoms in long COVID, also known as Post-Covid Condition or Post-Acute Sequelae of COVID-19 (PASC), and their causes are currently unknown. Previous studies have shown reduced blood flow and increased inflammation in the brains of people with PASC. These brain processes are related to fatigue and cognitive problems.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT07285707
Sponsor: Southern California University of Health Sciences (Academic / non-profit / other)
Intervention(s): Acupuncture
Start: Sep 2025  |  Primary completion: Dec 2026  |  Enrollment: 10 (estimated)
Record last updated: Dec 2025

List of the Hypothesis: Primary hypothesis: A flexible acupuncture and Chinese herbal medicine protocol will be feasible, acceptable, and useful for the treatment of long COVID. Secondary hypothesis: Long COVID patients receiving acupuncture treatment or acupuncture treatment and Chinese herbal supplements over an 8-week period will see improvements in their symptoms, function, and quality of life measurements.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT07278388
Sponsor: Hugo W. Moser Research Institute at Kennedy Krieger, Inc. (Academic / non-profit / other)
Intervention(s): Physical Fatigue
Start: Jul 2025  |  Primary completion: Dec 2029  |  Enrollment: 200 (estimated)
Record last updated: Dec 2025

This proposal aims to understand the neurobiological mechanisms of fatigue in individuals with Post-Acute Sequelae of SARS-CoV-2 Infection (PASC). This knowledge will eventually provide candidate mechanisms to target with pharmacological intervention and inform rehabilitative care for those individuals suffering from symptoms of fatigue in PASC.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT05566483
Sponsor: University of Colorado, Denver (Academic / non-profit / other)
Intervention(s): Exercise
Start: Mar 2023  |  Primary completion: Oct 2027  |  Enrollment: 30 (estimated)
Record last updated: Dec 2025

The primary objectives of this study are to determine whether exercise training is an effective strategy for treatment of Long COVID and characterize the cardiorespiratory and autonomic physiology in these patients to precisely characterize mechanisms contributing to this syndrome.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT07110714
Sponsor: Eggensberger OHG (Industry)
Intervention(s): Cold Water Hydrotherapy
Start: Dec 2025  |  Primary completion: Jan 2027  |  Enrollment: 30 (estimated)
Record last updated: Dec 2025

This randomized controlled study evaluates the effects of cold water hydrotherapy in patients with Post-COVID Syndrome. The primary aim is to assess changes in quality of life compared to an usual care setting without hydrotherapy treatment.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT05931497
Sponsor: Massachusetts General Hospital (Academic / non-profit / other)
Intervention(s): Whole Body Hyperthermia
Start: Aug 2026  |  Primary completion: Sep 2026  |  Enrollment: 21 (estimated)
Record last updated: Nov 2025

Research suggests that Whole Body Hyperthermia in a sauna-like environment can reduce symptoms related to post-acute sequelae of SARS-CoV-2 (PASC), or Long Covid. The investigators aim to study the feasibility and treatment effect of this procedure for patients experiencing Long Covid symptoms.

View on ClinicalTrials.gov ↗
RecruitingPhase 2 NCT06366724
Sponsor: Brigham and Women's Hospital (Academic / non-profit / other)
Start: Sep 2024  |  Primary completion: Sep 2026  |  Enrollment: 160 (estimated)
Record last updated: Oct 2025

The LIFT will be conducted at Brigham and Women's Hospital (BWH) of Harvard Medical School, focusing on the effect of Pyridostigmine (Mestinon) and Low-Dose Naltrexone (LDN) in subjects aged 18-70 meeting the Canadian consensus criteria (CCC) for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) as well as having specifically Orthostatic Intolerance (OI).

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT06928506
Sponsor: University Health Network, Toronto (Academic / non-profit / other)
Intervention(s): Hi-Oxsr Device, Hi-Ox Device
Start: Aug 2025  |  Primary completion: Dec 2027  |  Enrollment: 120 (estimated)
Record last updated: Sep 2025

The RECLAIM study platform will be used to explore whether the use of the Hi-OxSR device improves the symptoms of post covid cognitive dysfunction. Carbon dioxide (CO2) has been proposed as a potential treatment for persistent immune activation as there is evidence that CO2 has antioxidant, anti-inflammatory, and anti-cytokine effects.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT07154199
Sponsor: Xuanwu Hospital, Beijing (Academic / non-profit / other)
Intervention(s): Real Transcranial Ultrasound Stimulation
Start: Jan 2023  |  Primary completion: Dec 2027  |  Enrollment: 40 (estimated)
Record last updated: Sep 2025

This study aims to investigate whether a specific brain region mediates the cognitive deficit in long COVID brain fog, and whether targeted modulation of this region can improve cognition. In observational study, the objective was to identify potential intervention targets for patients with long COVID brain fog. A total of 120 patients with long COVID were enrolled.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT06156176
Sponsor: Lawson Research Institute of St. Joseph's (Academic / non-profit / other)
Intervention(s): Covidex
Start: Apr 2025  |  Primary completion: Apr 2026  |  Enrollment: 60 (estimated)
Record last updated: Aug 2025

Long COVID is a complex condition that affects approximately 1.4 million Canadians following SARS-CoV-2 infection. Fatigue is the most common symptom of Long COVID. This feasibility trial will evaluate a new rehabilitation program called COVIDEx for treating fatigue after COVID-19, and compare its effectiveness to the standard treatment currently used.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT06928480
Sponsor: Instituto de Investigación Sanitaria Aragón (Academic / non-profit / other)
Intervention(s): Unified Protocol For The Transdiagnostic Treatment Of Emotional Disorders, Treatment As Usual
Start: May 2025  |  Primary completion: Dec 2026  |  Enrollment: 90 (estimated)
Record last updated: May 2025

This Randomized Controlled Trial (RCT) aims to assess the effectiveness and acceptability of the Unified Protocol (UP) in an online group format for the treatment of emotional disorders in adults. Participants will be 90 adults (45 in the control group and 45 in the experimental group) with diagnosis of long COVID and comorbid emotional disorders.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT05741112
Sponsor: Scripps Translational Science Institute (Academic / non-profit / other)
Intervention(s): Wearable Device
Start: Nov 2023  |  Primary completion: Dec 2025  |  Enrollment: 100500 (estimated)
Record last updated: May 2025

To further characterize Long COVID-19 by collecting data from individuals who already own wearable devices or are provided with a wearable device along with basic and enhanced educational materials to determine if both can improve Long COVID-19 symptom management and post-exertional malaise.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT06522750
Sponsor: University of Luxembourg (Academic / non-profit / other)
Intervention(s): 7-Day Ambulatory Caloric Restriction Intervention Using The Buchinger-Wilhelmi Method
Start: Feb 2025  |  Primary completion: Jun 2025  |  Enrollment: 20 (estimated)
Record last updated: Mar 2025

Long COVID, characterized by persistent symptoms following acute COVID-19 infection, has emerged as a significant public health concern. Symptoms range from fatigue, cognitive impairments, to respiratory difficulties, affecting patients\' quality of life. Dietary interventions, particularly fasting, have historically been used to modulate immune responses and improve health outcomes in various conditions.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT06883513
Sponsor: University of Louisville (Academic / non-profit / other)
Intervention(s): Osteopathic Manipulative Therapy Long-Covid Protocol, Osteopathic Manipulative Therapy Not Long-Covid Treatment Protocol
Start: May 2025  |  Primary completion: Jul 2025  |  Enrollment: 20 (estimated)
Record last updated: Mar 2025

This study is investigating the effects of using an Osteopathic Manipulative Therapy (OMT) treatment protocol that was shown to statistically improve smell in individuals suffering from Long-COVID olfactory (smell) dysfunction in a small single-blinded pilot trial conducted during 2021. The questions this study is trying to answer are: 1. Does this OMT protocol improve other non-smell related Long-COVID symptoms 2.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT06876948
Sponsor: Azienda Ospedaliero, Universitaria Pisana (Academic / non-profit / other)
Intervention(s): Psychological Tests, Eeg, Magnetic Resonance
Start: Mar 2023  |  Primary completion: Mar 2025  |  Enrollment: 100 (estimated)
Record last updated: Mar 2025

The study seeks to investigate the neurological effects caused by Covid-19 in children and adolescents in the 6-16 age group. To do this, neuropsychological scales, an EEG and an MRI were used.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT05833217
Sponsor: Stanford University (Academic / non-profit / other)
Intervention(s): Adipose Tissue Biopsy, Steady State Plasma Glucose (Sspg) Test
Start: Jun 2023  |  Primary completion: May 2025  |  Enrollment: 55 (estimated)
Record last updated: Dec 2024

The investigators are studying the pathophysiologic links between obesity, insulin resistance (IR), adipose tissue infection, and post-acute sequelae of COVID-19 (PASC). This study looks at whether adipose (fat) tissue contributes to PASC by driving chronic inflammation or by serving as a reservoir for SARS-CoV-2 persistence.

View on ClinicalTrials.gov ↗
RecruitingPhase 4 NCT06441955
Sponsor: Well- Konnect Healthcare Services and Research Firm (Research network)
Intervention(s): Paxlovid (Nirmatrelvir/Ritonavir), Physiological Evaluation, Moderna Covid-19 Vaccine, Biopsychological, Behavioral, Genetic, Multidisciplinary Approach
Start: Mar 2024  |  Primary completion: Sep 2030  |  Enrollment: 100 (estimated)
Record last updated: Nov 2024

Investigators are conducting a study on alternative treatments for patients who have received an current or previous positive COVID-19 diagnosis with mild-serve symptoms or undiagnosable condition after testing positive for severe acute COVID-19 infection and are experiencing long-haul symptoms.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT05268523
Sponsor: Toronto Rehabilitation Institute (Academic / non-profit / other)
Intervention(s): Mindfulness Skills Intervention
Start: Nov 2021  |  Primary completion: Jun 2025  |  Enrollment: 270 (estimated)
Record last updated: Nov 2024

The purpose of this study is to investigate and compare the feasibility and efficacy of two group-based interventions (education vs. mindfulness) to help self-manage Long-COVID symptoms.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT06633666
Sponsor: Hong Kong Baptist University (Academic / non-profit / other)
Intervention(s): Acupuncture
Start: Jul 2023  |  Primary completion: Jan 2026  |  Enrollment: 160 (estimated)
Record last updated: Nov 2024

In this study, a 12-week pragmatic, randomized, double-blinded clinical trial will be conducted to evaluate the efficacy of acupuncture for the treatment of long Covid neuropsychiatric symptoms and provide reference for clinical non-drug treatment.

View on ClinicalTrials.gov ↗
RecruitingPhase not applicable NCT06311435
Sponsor: MaxWell Clinic, PLC (Industry)
Intervention(s): Rna Biomarker Blood Test
Start: Mar 2024  |  Primary completion: Mar 2026  |  Enrollment: 224 (estimated)
Record last updated: Oct 2024

The Primary objective of this study is to determine, using unblinded samples, if it is possible to develop an algorithm for the classification of specific blood RNA from patients with long COVID together and separately from the apparent health normal controls and other medical conditions that share the signs and symptoms of long COVID.

View on ClinicalTrials.gov ↗

Not yet recruiting (25)

Not yet recruitingPhase 1 NCT07388550
Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) (NIH)
Intervention(s): Keytruda
Start: Oct 2026  |  Primary completion: Jan 2028  |  Enrollment: 15 (estimated)
Record last updated: Oct 2026

SARS-CoV-2 is the virus that causes COVID-19. Some people who recover from an acute COVID-19 infection may continue to have symptoms that persist for months or years. These can include neurological symptoms, such as headaches, loss of taste or smell, dizziness, or trouble walking.

View on ClinicalTrials.gov ↗
Not yet recruitingPhase not applicable NCT07798570
Sponsor: University Hospital Schleswig-Holstein (Academic / non-profit / other)
Intervention(s): Cicr-Nam
Start: Sep 2026  |  Primary completion: Jun 2028  |  Enrollment: 100 (estimated)
Record last updated: Sep 2026

In patients with post-COVID syndrome, changes in tryptophan metabolism, energy metabolism, and the gut microbiome may occur. In an earlier nutritional study, patients with COVID-19 recovered their physical performance more quickly when taking nicotinamide (vitamin B3). Patients who responded to nicotinamide also developed post-COVID syndrome less frequently.

View on ClinicalTrials.gov ↗
Not yet recruitingPhase 1 NCT07682402
Sponsor: University of Alberta (Academic / non-profit / other)
Intervention(s): Taurine
Start: Sep 2026  |  Primary completion: Mar 2028  |  Enrollment: 30 (estimated)
Record last updated: Aug 2026

The COVID-19 pandemic has swept across the globe, affecting millions of individuals with varying degrees of severity. While many individuals recover from the acute phase of the infection, a significant proportion continue to experience persistent and debilitating symptoms long after the initial SARS-CoV-2 infection.

View on ClinicalTrials.gov ↗
Not yet recruitingPhase 2 NCT07724834
Sponsor: Charite University, Berlin, Germany (Academic / non-profit / other)
Intervention(s): Inebilizumab
Start: Dec 2026  |  Primary completion: Feb 2029  |  Enrollment: 38 (estimated)
Record last updated: Jul 2026

Post-acute infection syndromes (PAIS) are long-lasting health problems that can develop after an infection. They include post-COVID-19 syndrome and similar illnesses following other infections. Some people with PAIS develop myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), a serious and disabling illness that can greatly limit everyday activities.

View on ClinicalTrials.gov ↗
Not yet recruitingPhase not applicable NCT07709234
Sponsor: University of Las Palmas de Gran Canaria (Academic / non-profit / other)
Start: Sep 2026  |  Primary completion: Dec 2027  |  Enrollment: 20 (estimated)
Record last updated: Jul 2026

Long COVID can cause persistent symptoms such as fatigue, cognitive difficulties commonly described as brain fog, reduced exercise tolerance, and impaired quality of life. Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation technique that may help modulate brain activity in regions involved in cognition, fatigue, and executive function.

View on ClinicalTrials.gov ↗
Not yet recruitingPhase 2 NCT07714213
Sponsor: Christiana Franke (Academic / non-profit / other)
Intervention(s): Aripiprazole
Start: Oct 2026  |  Primary completion: May 2028  |  Enrollment: 138 (estimated)
Record last updated: Jul 2026

Post-acute infectious syndrome (PAIS), including post-COVID-19 condition (PCC or Long COVID), can develop after an infection and may cause persistent symptoms such as fatigue, problems with memory and concentration ("brain fog"), mood changes, and reduced quality of life. In some people, these symptoms continue for months or longer and can substantially affect daily activities.

View on ClinicalTrials.gov ↗
Not yet recruitingPhase not applicable NCT07697261
Sponsor: McMaster University (Academic / non-profit / other)
Intervention(s): Lightning Process, Activity Pacing
Start: Nov 2026  |  Primary completion: Dec 2028  |  Enrollment: 100 (estimated)
Record last updated: Jul 2026

Long COVID affects about 6 in 100 people after a COVID-19 infection. It can cause ongoing problems like ongoing tiredness, muscle pain, and "brain fog." We know very little about which treatments might be helpful for long COVID. The goal of this trial is to compare two treatments for people with long COVID to try to manage their symptoms.

View on ClinicalTrials.gov ↗
Not yet recruitingPhase not applicable NCT07694232
Sponsor: St. Mary's University, Twickenham (Academic / non-profit / other)
Intervention(s): Treatment A: Treatment By A Homeopath Prescribing A Specific Homeopathic Remedy For Long Covid, A Course Of Individually Tailored Treatment By A Homeopath
Start: Jul 2026  |  Primary completion: Jul 2028  |  Enrollment: 120 (estimated)
Record last updated: Jul 2026

A small-scale test of the intervention, trial design and methods to explore the cumulative effectiveness of two commonly used prescribing strategies for patients with long COVID: Treatment A - prescribing a specific homeopathic remedy for long COVID, plus or minus Treatment B - a course of individually tailored treatment by a homeopath. Both interventions compared to usual care.

View on ClinicalTrials.gov ↗
Not yet recruitingPhase 3 NCT06907251
Sponsor: Ottawa Heart Institute Research Corporation (Academic / non-profit / other)
Intervention(s): Dapagliflozin
Start: Sep 2026  |  Primary completion: Jun 2028  |  Enrollment: 192 (estimated)
Record last updated: Jul 2026

This is a randomized, placebo-controlled study. Patients with long COVID will be randomized to receive dapagliflozin or placebo for 12 months.

View on ClinicalTrials.gov ↗
Not yet recruitingPhase 2 NCT06974084
Sponsor: HealthBio, Inc. (Industry)
Intervention(s): Maraviroc, Atorvastatin, 10Mg, 20Mg, 40Mg
Start: Jul 2026  |  Primary completion: Dec 2026  |  Enrollment: 252 (estimated)
Record last updated: Jun 2026

The IMPACT Long Covid Treatment clinical study (IMPACT-LC) is testing two repurposed and previously approved drugs, Maraviroc and Atorvastatin, for the treatment of non-hospitalized subjects with Long COVID.

View on ClinicalTrials.gov ↗
Not yet recruitingPhase 2 NCT07597902
Sponsor: Icahn School of Medicine at Mount Sinai (Academic / non-profit / other)
Intervention(s): Valacyclovir, Celecoxib, Paxlovid (Nirmatrelvir/Ritonavir)
Start: Jun 2026  |  Primary completion: Jun 2028  |  Enrollment: 150 (estimated)
Record last updated: May 2026

The purpose of this research study is to test if the combination of three drugs, valacyclovir, celecoxib, and Paxlovid will decrease the symptoms of Long COVID in adults compared to a placebo (this does not contain the medications).

View on ClinicalTrials.gov ↗
Not yet recruitingPhase not applicable NCT07216040
Sponsor: Icahn School of Medicine at Mount Sinai (Academic / non-profit / other)
Intervention(s): Hope-Lc~Espanol
Start: May 2026  |  Primary completion: Aug 2026  |  Enrollment: 25 (estimated)
Record last updated: Apr 2026

The Harnessing Optimism and Perseverance in the Face of Long COVID (HOPE-LC) program, created by Drs. Eric Watson and Amelia Hicks, is a group therapy model designed to foster resilience, adjustment, and coping skills for those living with chronic Long COVID.

View on ClinicalTrials.gov ↗
Not yet recruitingPhase not applicable NCT07397910
Sponsor: Universidad Católica San Antonio de Murcia (Academic / non-profit / other)
Intervention(s): Experimental Product, Physical Exercise, No Physical Exercise
Start: Feb 2026  |  Primary completion: Jul 2026  |  Enrollment: 40 (estimated)
Record last updated: Feb 2026

A controlled, randomized clinical trial is proposed to demonstrate the effectiveness of the experimental product in controlling hepato-pulmonary inflammation and neurovascular encephalic inflammation, which may constitute the etiopathogenic basis of persistent COVID.

View on ClinicalTrials.gov ↗
Not yet recruitingPhase not applicable NCT07355751
Sponsor: Tingting Luo (Academic / non-profit / other)
Intervention(s): Acupuncture
Start: May 2026  |  Primary completion: Dec 2027  |  Enrollment: 108 (estimated)
Record last updated: Jan 2026

Background of study: Long COVID(LC) is a prevalent sequalae of SARS-CoV-2 infection and can affect multiple organ systems. Cognitive dysfunction is one of the most common symptoms in LC with 22% prevalence. It can persist for years and significantly reduce patients' quality of life.

View on ClinicalTrials.gov ↗
Not yet recruitingPhase not applicable NCT07312357
Sponsor: Universidad Rey Juan Carlos (Academic / non-profit / other)
Intervention(s): Whole-Body Electromyostimulation Suit
Start: Mar 2026  |  Primary completion: Sep 2026  |  Enrollment: 30 (estimated)
Record last updated: Dec 2025

Post-COVID syndrome is a condition that affects some people after recovering from the acute phase of COVID-19. Common symptoms include persistent fatigue, reduced physical capacity, and difficulties performing everyday activities, which can significantly impact quality of life and independence. At present, there is limited scientific evidence on effective rehabilitation strategies for this population.

View on ClinicalTrials.gov ↗
Not yet recruitingPhase not applicable NCT07079787
Sponsor: University College, London (Academic / non-profit / other)
Intervention(s): Telerehab Dss Pilot Test
Start: Jul 2025  |  Primary completion: Aug 2025  |  Enrollment: 30 (estimated)
Record last updated: Jul 2025

This study follows the successfully completed HOLOBalance project which was funded by the EU Horizon 2020 scheme. TheHOLOBalance platform delivers exercises demonstrated via a hologram of the physiotherapist and corrected in real time by the hologram prompts based on performance monitoring via sensors. Further information is available at: https://holobalance.eu/.

View on ClinicalTrials.gov ↗
Not yet recruitingPhase not applicable NCT06534164
Sponsor: University College, London (Academic / non-profit / other)
Intervention(s): Full/High Tech Telerehabilitation Decision Support System, Basic/Low Tech Telerehabilitation Decision Support System, Otago Home Exercise Program, Vestibular Rehabilitation Program
Start: Sep 2025  |  Primary completion: Jun 2026  |  Enrollment: 460 (estimated)
Record last updated: Jul 2025

This study follows the successfully completed HOLOBalance project which was funded by the EU Horizon 2020 scheme. TheHOLOBalance platform delivers exercises demonstrated via a hologram of the physiotherapist and corrected in real time by the hologram prompts based on performance monitoring via sensors. Further information is available at: https://holobalance.eu/.

View on ClinicalTrials.gov ↗
Not yet recruitingPhase not applicable NCT07046208
Sponsor: Universidade do Estado do Pará (Academic / non-profit / other)
Intervention(s): Physiothreapy Protocol
Start: Aug 2025  |  Primary completion: Aug 2026  |  Enrollment: 58 (estimated)
Record last updated: Jul 2025

Introduction: Long COVID is characterized by persistent symptoms that persist for weeks or months after the acute phase of infection, with a significant impact on the cardiovascular and autonomic systems. Objectives: This study aims to evaluate the effects of a physiotherapeutic rehabilitation protocol on cardiovascular autonomic modulation and on inflammatory and cardiac biomarkers in patients with Long COVID.

View on ClinicalTrials.gov ↗
Not yet recruitingPhase not applicable NCT06996314
Sponsor: Ali Kapan (Academic / non-profit / other)
Intervention(s): Tvns + Slow-Paced Breathing, Tvns Without Breathing Training
Start: Sep 2025  |  Primary completion: Mar 2028  |  Enrollment: 100 (estimated)
Record last updated: Jun 2025

This study investigates a non-pharmacological treatment approach for Postural Orthostatic Tachycardia Syndrome (POTS), a disorder of the autonomic nervous system characterized by an excessive increase in heart rate upon standing.

View on ClinicalTrials.gov ↗
Not yet recruitingPhase not applicable NCT06992414
Sponsor: University of Calgary (Academic / non-profit / other)
Intervention(s): Creatine Monohydrate
Start: Jul 2025  |  Primary completion: Jun 2026  |  Enrollment: 24 (estimated)
Record last updated: May 2025

Individuals living with Long COVID often experiencing a degree of undue fatigue after physical or cognitive exertion secondary to the condition, timed post-exertional malaise 9PEM). This trial aims to explore the efficacy of creatine monohydrate in managing PEM.

View on ClinicalTrials.gov ↗
Not yet recruitingPhase 2 NCT06967428
Sponsor: Independent Medical Alliance (Academic / non-profit / other)
Intervention(s): Combined Metabolic Modulator, Rice Protein Powder With Vitamin C
Start: Sep 2025  |  Primary completion: Jan 2026  |  Enrollment: 100 (estimated)
Record last updated: May 2025

The goal of this clinical trial is to evaluate whether metabolic modulation with a combined nutraceutical product can improve symptoms and metabolic health in adults diagnosed with post-acute Covid-19 vaccination syndrome (PACVS), a condition characterized by persistent fatigue and exercise intolerance attributed to Covid-19 vaccination and confirmed by laboratory testing.

View on ClinicalTrials.gov ↗
Not yet recruitingPhase not applicable NCT06597682
Sponsor: Huashan Hospital (Academic / non-profit / other)
Intervention(s): Prednisone, Budesonide/Formoterol, Vitamin C Combined With Coenzyme Q10 Oral Treatment, Montelukast Tablets Oral Treatment
Start: Mar 2025  |  Primary completion: Jul 2027  |  Enrollment: 632 (estimated)
Record last updated: Mar 2025

This study is a prospective, randomized controlled, basket trial. Patients diagnosed with Post-Acute Sequelae of SARS-CoV-2 Infection who meet the inclusion and exclusion criteria are recruited and divided into three symptom clusters: Inflammatory Cardiac involvement symptoms cluster, cough symptoms cluster and fatigue symptoms cluster.

View on ClinicalTrials.gov ↗
Not yet recruitingPhase not applicable NCT06765421
Sponsor: University College Dublin (Academic / non-profit / other)
Intervention(s): Intervention Group
Start: Mar 2025  |  Primary completion: Apr 2025  |  Enrollment: 72 (estimated)
Record last updated: Jan 2025

This trial will evaluate the feasibility of a pilot educational intervention for GPs that aims to enhance care and care outcomes among patients with long COVID at six general practices in the Ireland East region. Our first objective is to conduct focus groups with key stakeholders (GPs, other health professionals, patients, families/carers) that will inform the contents of an education intervention.

View on ClinicalTrials.gov ↗
Not yet recruitingPhase 2 NCT05597800
Sponsor: Universita di Verona (Academic / non-profit / other)
Intervention(s): Nivolumab And Ipilimumab
Start: Feb 2023  |  Primary completion: Dec 2026  |  Enrollment: 105 (estimated)
Record last updated: Oct 2022

Study type: Phase 2 - Interventional Trial Number of patients to be enrolled: 105 Participating countries: Italy Study drugs: nivolumab and ipilimumab Cohort A: HBV and HCV patients Cohort B: HIV patients Cohort C: Long COVID syndrome The stratification factors are HBV/HCV positive (cohort A), HIV positive (cohort B), patients with Long Covid syndrome (Cohort C), histology (squamous vs non-squamous histology), and gender (male vs female).

View on ClinicalTrials.gov ↗

Enrolling by invitation (3)

Enrolling by invitationPhase not applicable NCT06086379
Sponsor: VA Office of Research and Development (US federal agency)
Intervention(s): Compensatory Cognitive Training For Covid-19
Start: Jul 2024  |  Primary completion: Jun 2027  |  Enrollment: 70 (estimated)
Record last updated: Jul 2026

Cognitive dysfunction, psychiatric symptoms, functional impairment, and disability following COVID-19 negatively impact Veterans' community functioning and quality of life, contribute to significant human suffering, and are costly to VHA. Rehabilitation is a critical priority for Veterans with long COVID.

View on ClinicalTrials.gov ↗
Enrolling by invitationPhase not applicable NCT06560554
Sponsor: Mayo Clinic (Academic / non-profit / other)
Intervention(s): Fermented Foods
Start: Sep 2024  |  Primary completion: Sep 2025  |  Enrollment: 40 (estimated)
Record last updated: Jun 2026

The purpose of this study is to evaluate the effects of fermented foods on bacterial gut microbiome diversity of long-COVID subjects.

View on ClinicalTrials.gov ↗
Enrolling by invitationPhase not applicable NCT07343856
Sponsor: Oncology Center,Ministry Of Heath,Uzbekistan (Academic / non-profit / other)
Intervention(s): Electrodiagnostic Bioelectrical Assessment
Start: Dec 2025  |  Primary completion: Dec 2026  |  Enrollment: 50 (estimated)
Record last updated: Jan 2026

This study is a diagnostic clinical investigation designed to evaluate bioelectrical response patterns assessed by electro-acupuncture-based medicament testing. The method is used to identify individual bioelectrical reactivity associated with the presence and persistence of pathological factors and to assess patient-specific responses to tested medicinal substances.

View on ClinicalTrials.gov ↗

Active, not recruiting (26)

Active, not recruitingPhase not applicable NCT06585254
Sponsor: Icahn School of Medicine at Mount Sinai (Academic / non-profit / other)
Intervention(s): Transcutaneous Vagus Nerve Stimulator
Start: Nov 2024  |  Primary completion: Dec 2026  |  Enrollment: 50 (estimated)
Record last updated: Aug 2026

A prior open label study has shown that transcutaneous vagus nerve stimulation \[tVNS\] can improve the health of some patients with postacute sequelae of SARS-CoV-2 infection (PASC), severely affected enough to also fulfill criteria for myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS).

View on ClinicalTrials.gov ↗
Active, not recruitingPhase not applicable NCT05705648
Sponsor: University of Alberta (Academic / non-profit / other)
Intervention(s): Medium Chain Triglyceride Oil, Safflower Oil
Start: Oct 2023  |  Primary completion: Jun 2026  |  Enrollment: 103 (actual)
Record last updated: Jul 2026

The goal of this clinical trial is to learn about in brain "fog" complaints associated with long-COVID in people aged 22-50-years. The main questions it aims to answer are: * the natural course of brain "fog" complaints * the effect, if any of supplemental dietary oil on brain "fog" complaints Participants will be asked to undergo some brain testing (X-rays and questions.

View on ClinicalTrials.gov ↗
Active, not recruitingPhase not applicable NCT05092516
Sponsor: Massachusetts General Hospital (Academic / non-profit / other)
Intervention(s): Active Tdcs
Start: Jun 2022  |  Primary completion: Mar 2025  |  Enrollment: 31 (actual)
Record last updated: Jul 2026

The main goal of this study is to improve dysexecutive symptoms (e.g., sustained attention, processing speed) in patients exhibiting post-acute sequelae of COVID-19 (PASC) through home-based transcranial direct current stimulation (tDCS), a noninvasive method that uses low intensity electric currents delivered to the brain through stimulation electrodes on the scalp.

View on ClinicalTrials.gov ↗
Active, not recruitingPhase not applicable NCT05877534
Sponsor: Karolinska Institutet (Academic / non-profit / other)
Intervention(s): Individual Tailored Exercise
Start: May 2023  |  Primary completion: Oct 2025  |  Enrollment: 60 (estimated)
Record last updated: Jul 2026

Covid-19 has the potential to affect physical, cognitive and psychological functions in multiple ways. It has been clear that a significant proportion of patients with Covid-19 develop long-term symptoms. The term post COVID-19 condition (defined by WHO) is used to describe the wide range of prolonged symptoms following the infection.

View on ClinicalTrials.gov ↗
Active, not recruitingPhase not applicable NCT05421208
Sponsor: Vanderbilt University Medical Center (Academic / non-profit / other)
Intervention(s): Effect On Inflammation After Chronic Pns Stimulation
Start: Jun 2022  |  Primary completion: Jul 2026  |  Enrollment: 60 (actual)
Record last updated: Jul 2026

The term post-acute COVID-19 syndrome or Long COVID is a disabling syndrome that persists beyond the 3-month convalescence period after COVID-19 infections. This syndrome affects mostly women (\~80%), present with chronic tachycardia and Orthostatic intolerance symptoms without any identifiable cause.

View on ClinicalTrials.gov ↗
Active, not recruitingPhase 2 NCT06766825
Sponsor: Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia (Academic / non-profit / other)
Intervention(s): Plitidepsin 1.5 Mg/Day
Start: Feb 2025  |  Primary completion: Sep 2026  |  Enrollment: 90 (estimated)
Record last updated: Jul 2026

The study aims to prove that plitidepsin could be an efficacious, safe, and well-tolerated therapy for PCC. To this end, we will perform a randomized, double-blind study comparing the clinical and laboratory benefits of plitidepsin vs. placebo in 90 subjects with moderate to severe functional disability.

View on ClinicalTrials.gov ↗
Active, not recruitingPhase not applicable NCT06231238
Sponsor: King's College London (Academic / non-profit / other)
Intervention(s): Balance Acceptance And Commitment Therapy
Start: Jun 2024  |  Primary completion: May 2026  |  Enrollment: 196 (estimated)
Record last updated: Jul 2026

This randomised controlled trial aims to investigate the efficacy of a psychological intervention for long COVID (LC) / post-COVID-19 syndrome (PCS) called Balance Acceptance and Commitment Therapy (Balance ACT). The primary objective of this trial is to investigate whether Balance-ACT improves quality of life over treatment as usual (i.e., self-help leaflet) in people with PCS/LC.

View on ClinicalTrials.gov ↗
Active, not recruitingPhase not applicable NCT05676008
Sponsor: University of California, Davis (Academic / non-profit / other)
Intervention(s): Microdosing Of Mindfulness
Start: Jan 2023  |  Primary completion: Apr 2027  |  Enrollment: 400 (estimated)
Record last updated: May 2026

This study is testing a new brief mindfulness practice for people suffering from long COVID-19 symptoms. People suffering from long COVID are particularly vulnerable to negative emotions, as they must also cope with the long-term uncertainty of physical and psychological stress beyond the acute infection.

View on ClinicalTrials.gov ↗
Active, not recruitingPhase not applicable NCT07559994
Sponsor: Fundacion Investigacion Interhospitalaria Cardiovascular (Academic / non-profit / other)
Intervention(s): Coronary Functional Test
Start: Sep 2021  |  Primary completion: Apr 2025  |  Enrollment: 108 (estimated)
Record last updated: May 2026

Long Covid-19 INOCA is an investigator-initiated, prospective, randomized, sham-controlled, single center study.

View on ClinicalTrials.gov ↗
Active, not recruitingPhase not applicable NCT06978582
Sponsor: University of Seville (Academic / non-profit / other)
Intervention(s): Mindful And Conscious Movement-Based Exercise, Conventional Exercise
Start: Oct 2025  |  Primary completion: Dec 2026  |  Enrollment: 147 (estimated)
Record last updated: Apr 2026

This is a randomized, single-blind clinical trial that aims to evaluate the effectiveness of a tele-rehabilitation program based on mindful and conscious movement-based exercise (including adapted yoga, breathing exercises, and body awareness) compared to conventional exercise (low-intensity strength and aerobic training) and usual medical care (control group) over twelve weeks.

View on ClinicalTrials.gov ↗
Active, not recruitingPhase 2 NCT06597396
Sponsor: Beth Israel Deaconess Medical Center (Academic / non-profit / other)
Intervention(s): Abrocitinib
Start: Dec 2024  |  Primary completion: Mar 2026  |  Enrollment: 46 (actual)
Record last updated: Apr 2026

The primary purpose of this phase 2a study is to compare the efficacy of abrocitinib to placebo in improving severe fatigue in non-hospitalized adults with symptomatic Post-COVID Condition (PCC) (also called Long COVID). We are also interested in learning if abrocitinib is effective in improving overall health status in people suffering from severe fatigue from PCC.

View on ClinicalTrials.gov ↗
Active, not recruitingPhase 2 NCT06161688
Sponsor: Timothy Henrich (Academic / non-profit / other)
Intervention(s): Ensitrelvir
Start: Apr 2024  |  Primary completion: Dec 2024  |  Enrollment: 40 (actual)
Record last updated: Apr 2026

Persistent viral infection with viral reservoirs and detection of circulating spike protein after the initial acute illness is one potential pathogenic mechanism for Long COVID. This mechanism may be susceptible to antiviral therapy that blocks viral replication, which has the potential to alleviate long COVID symptoms.

View on ClinicalTrials.gov ↗
Active, not recruitingPhase not applicable NCT06391489
Sponsor: Dartmouth-Hitchcock Medical Center (Academic / non-profit / other)
Intervention(s): Hobscotch-Pacs
Start: May 2024  |  Primary completion: Dec 2026  |  Enrollment: 10 (actual)
Record last updated: Feb 2026

The goal of this pilot study is to assess the feasibility of adapting and delivering the existing home-based epilepsy self-management intervention, HOBSCOTCH, for people with Post Acute Covid Syndrome (PACS). The main questions it aims to answer are: Can the current HOBSCOTCH program be adapted for people with PACS?

View on ClinicalTrials.gov ↗
Active, not recruitingPhase 2 NCT07128082
Sponsor: Scripps Translational Science Institute (Academic / non-profit / other)
Intervention(s): Tirzepatide
Start: Oct 2025  |  Primary completion: Dec 2026  |  Enrollment: 1000 (actual)
Record last updated: Dec 2025

The goal of this study is to determine whether a medicine called tirzepatide, also called Zepbound, can reduce symptoms of Long COVID. A randomized control trial will allow us to measure the effect of the treatment by having half of the participants take the medication and half take a placebo that has no medication.

View on ClinicalTrials.gov ↗
Active, not recruitingPhase 2 NCT04948203
Sponsor: University of Chicago (Academic / non-profit / other)
Intervention(s): Sirolimus (low-dose)
Start: Jul 2021  |  Primary completion: Dec 2026  |  Enrollment: 60 (estimated)
Record last updated: Dec 2025

The primary purpose of this study is to determine whether the drug sirolimus reduces the likelihood of developing of pulmonary fibrosis in patients who are hospitalized with COVID-19 pneumonia.

View on ClinicalTrials.gov ↗
Active, not recruitingPhase not applicable NCT07254377
Sponsor: I.R.C.C.S. Fondazione Santa Lucia (Academic / non-profit / other)
Intervention(s): Dual Task Exercise, Physical Therapy
Start: Nov 2025  |  Primary completion: Mar 2026  |  Enrollment: 48 (estimated)
Record last updated: Dec 2025

People affected by Stroke, Multiple Sclerosis (MS), and Parkinson's disease (PD) share severe and complex disabilities. Widespread neuro-inflammatory processes represent an important pathogenetic component in all three conditions.

View on ClinicalTrials.gov ↗
Active, not recruitingPhase 3 NCT05619653
Sponsor: Valentina Puentmann (Academic / non-profit / other)
Intervention(s): Prednisolone, Losartan
Start: Dec 2022  |  Primary completion: Aug 2025  |  Enrollment: 279 (actual)
Record last updated: Dec 2025

Long COVID or Postacute sequelae of COVID-19 infection (PASC) are increasingly recognised complications, defined by lingering symptoms, not present prior to the infection, typically persisting for more than 4 weeks.

View on ClinicalTrials.gov ↗
Active, not recruitingPhase 3 NCT05852873
Sponsor: Haukeland University Hospital (Academic / non-profit / other)
Start: May 2023  |  Primary completion: Sep 2025  |  Enrollment: 2000 (estimated)
Record last updated: Nov 2025

The goal of this clinical trial is to compare treatment with oral Paxlovid (nirmatrelvir/ritonavir) and placebo for acute COVID-19 as an intervention to prevent long-COVID (post-COVID-19 condition) in adults aged 18-64 years old. The main question it aims to answer is: Does treatment with Paxlovid for acute COVID-19 reduce the prevalence of long-COVID compared to placebo.

View on ClinicalTrials.gov ↗
Active, not recruitingPhase 2 NCT05877508
Sponsor: Michael Peluso, MD (Academic / non-profit / other)
Intervention(s): Aer002
Start: Aug 2023  |  Primary completion: Jul 2024  |  Enrollment: 36 (actual)
Record last updated: Oct 2025

Persistent viral infection with viral reservoirs and detection of circulating spike protein after the initial acute illness is one potential pathogenic mechanism for Long COVID. This mechanism may be able to be targeted by SARS-CoV-2 monoclonal antibodies (mAbs). This trial will study the safety and efficacy of AER002 to treat individuals with Long COVID in an adult population.

View on ClinicalTrials.gov ↗
Active, not recruitingPhase not applicable NCT05813873
Sponsor: European University Cyprus (Academic / non-profit / other)
Intervention(s): Triflow
Start: Dec 2022  |  Primary completion: Dec 2025  |  Enrollment: 70 (estimated)
Record last updated: Aug 2025

The aim of this clinical trial is to investigate the efficacy of Triflow in the rehabilitation of patients with long covid syndrome hospitalised in a rehabilitation center. Participants will be divided into 2 groups and follow their exercise regime until the day they are discharged from the rehabilitation center.

View on ClinicalTrials.gov ↗
Active, not recruitingPhase not applicable NCT06968104
Sponsor: University of Luxembourg (Academic / non-profit / other)
Intervention(s): Transcutaneous Vagus Nerve Stimulation
Start: Jul 2025  |  Primary completion: Oct 2026  |  Enrollment: 48 (estimated)
Record last updated: Aug 2025

This study is testing whether a gentle electrical stimulation of a nerve in the ear, called the vagus nerve, can help reduce fatigue and improve symptoms in people with Post-COVID Syndrome or Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). The treatment, known as transcutaneous auricular vagus nerve stimulation (taVNS), is non-invasive and can be done at home using a small device.

View on ClinicalTrials.gov ↗
Active, not recruitingPhase not applicable NCT05167227
Sponsor: Family Health Centers of San Diego (Academic / non-profit / other)
Intervention(s): Extension For Community Healthcare Outcomes
Start: Nov 2021  |  Primary completion: Nov 2024  |  Enrollment: 20 (actual)
Record last updated: Aug 2025

The primary objective of the present research is to determine the effectiveness of Family Health Center of San Diego's Long COVID and Fatiguing Illness Recovery Program (LC\&FIRP) on clinician- and patient-level outcomes.

View on ClinicalTrials.gov ↗
Active, not recruitingPhase not applicable NCT06251518
Sponsor: Gaia AG (Industry)
Intervention(s): Vimida
Start: Feb 2025  |  Primary completion: Sep 2025  |  Enrollment: 160 (estimated)
Record last updated: Jun 2025

This randomized controlled trial (RCT) with 160 patients suffering from fatigue after COVID-19 infection aims to investigate the effectiveness of the unguided digital therapeutic vimida for reducing post-COVID-19 fatigue.

View on ClinicalTrials.gov ↗
Active, not recruitingPhase not applicable NCT05094622
Sponsor: Karolinska Institutet (Academic / non-profit / other)
Intervention(s): Physical Exercise Program
Start: Jan 2022  |  Primary completion: Dec 2023  |  Enrollment: 30 (estimated)
Record last updated: Apr 2025

Covid-19 has the potential to affect physical, cognitive and psychological functions in multiple ways. It has been clear that a significant proportion of patients with Covid-19 develop long-term symptoms. The term post-acute Covid-19 syndrome (PACS) is now used to describe the wide range of prolonged symptoms following the infection.

View on ClinicalTrials.gov ↗
Active, not recruitingPhase not applicable NCT06073002
Sponsor: University of Vienna (Academic / non-profit / other)
Intervention(s): Home-Based Concurrent Exercise
Start: Sep 2023  |  Primary completion: Feb 2025  |  Enrollment: 20 (estimated)
Record last updated: Dec 2024

The current Coronavirus Disease 2019 (COVID-19) pandemic is the most severe health crisis of the 21st century. This is not only due to the deaths caused by the disease. People that were affected by COVID-19 and supposedly recovered may suffer from long lasting sequelae.

View on ClinicalTrials.gov ↗
Active, not recruitingPhase 2 NCT05690503
Sponsor: New York State Psychiatric Institute (Academic / non-profit / other)
Intervention(s): Ci-581A, Ci-581B
Start: Mar 2023  |  Primary completion: Jun 2025  |  Enrollment: 12 (estimated)
Record last updated: Jul 2024

Post-acute sequelae of SARS-CoV2 (PASC), colloquially known as "long-COVID," is thought to affect between 10-30% of all COVID-19 survivors. Patients with PASC also report worsening behavioral health symptoms over time that include new-onset depression, anxiety, and even suicidal behavior.

View on ClinicalTrials.gov ↗

Completed (150)

CompletedPhase 2 NCT05874037
Sponsor: Washington University School of Medicine (Academic / non-profit / other)
Intervention(s): Fluvoxamine
Start: May 2023  |  Primary completion: Mar 2025  |  Enrollment: 191 (actual)
Record last updated: Oct 2026

This clinical trial aims to test the effects of fluvoxamine as a treatment for Long COVID. Fluvoxamine is an FDA approved SSRI for Obsessive Compulsive Disorder (OCD), that has already had success in preventing hospitalization in patients with COVID-19 (STOP COVID and TOGETHER trials).

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT06404073
Sponsor: Duke University (Academic / non-profit / other)
Intervention(s): Structured Pacing
Start: Jul 2024  |  Primary completion: Aug 2025  |  Enrollment: 300 (actual)
Record last updated: Oct 2026

This is a platform protocol designed to be flexible so that it is suitable for a range of interventions and settings within diverse health care systems and community settings with incorporation into clinical COVID-19 management programs and treatment plans if results achieve key study outcomes.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT07621588
Sponsor: Universidad Pontificia de Salamanca (Academic / non-profit / other)
Intervention(s): Diaphragmatic Electrostimulation Using Kots Currents, Diaphragmatic Breathing Exercises
Start: Jun 2026  |  Primary completion: Jul 2026  |  Enrollment: 9 (actual)
Record last updated: Sep 2026

This study will evaluate the effects of diaphragmatic breathing exercises combined with diaphragmatic electrostimulation using KOTS currents in patients with Long COVID. Participants will be randomly assigned to one of two groups.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT07005921
Sponsor: Jade Carvalho Da Silva (Academic / non-profit / other)
Intervention(s): Qeeg-Neurofeedback
Start: Jun 2025  |  Primary completion: Aug 2026  |  Enrollment: 40 (actual)
Record last updated: Sep 2026

The pandemic has highlighted social, economic, educational, and political issues that have affected the health and quality of life of millions of Brazilians. Currently, attention and memory impairment remains predominant among the cognitive symptoms of Coronavirus observed in adults. The persistance of the reffered impairment after 12 weeks of COVID-19 is known as cognitive impairment in post-COVID-19 syndrome.

View on ClinicalTrials.gov ↗
CompletedPhase 2 NCT06847191
Sponsor: BioVie Inc. (Industry)
Intervention(s): Ne3107
Start: Apr 2025  |  Primary completion: Aug 2026  |  Enrollment: 203 (actual)
Record last updated: Sep 2026

Long COVID is a condition where debilitating symptoms can persist for months after a COVID-19 infection. This study aims to evaluate the effects of NE3107 on several neurological symptoms reported in people with Long COVID including difficulty concentrating or remembering things ("brain fog") and fatigue. This study is designed as a signal-seeking proof-of-concept Phase 2 study.

View on ClinicalTrials.gov ↗
CompletedPhase 2 NCT06821087
Sponsor: University of Texas at Austin (Academic / non-profit / other)
Intervention(s): Ketamine Only
Start: Jun 2025  |  Primary completion: Jun 2026  |  Enrollment: 20 (actual)
Record last updated: Sep 2026

Plain Language Summary: This study is a clinical trial to see if ketamine can help treat symptoms of Long COVID, especially fatigue and problems with thinking clearly (often called "brain fog"). Long COVID is a condition that affects people even after they have recovered from COVID-19, causing ongoing health issues like tiredness, memory problems, and difficulty concentrating.

View on ClinicalTrials.gov ↗
CompletedPhase 2 NCT06822179
Sponsor: CEU San Pablo University (Academic / non-profit / other)
Intervention(s): Personalised Exercise Program
Start: Mar 2025  |  Primary completion: Jun 2026  |  Enrollment: 57 (actual)
Record last updated: Sep 2026

The goal of this clinical trial is to evaluate whether a 12-week tele-rehabilitation programme with monitoring via a mobile app produces medium-term improvements in self-management, fatigue and quality of life in patients affected by persistent COVID.

View on ClinicalTrials.gov ↗
CompletedPhase 2 NCT05618574
Sponsor: VA Office of Research and Development (US federal agency)
Intervention(s): 140 Ml Per Day Of Beet-It Nitrate Beverage
Start: Dec 2023  |  Primary completion: Feb 2025  |  Enrollment: 17 (actual)
Record last updated: Aug 2026

Potential benefits of a nitrate-rich juice supplement to improve skeletal muscle function and associated physical capacity will be studied in patients with Long COVID. Consenting patients with Long-COVID will be randomized to receive Beet-It nitrate beverage group versus a nitrate-depleted placebo beverage.

View on ClinicalTrials.gov ↗
CompletedPhase 2 NCT05703074
Sponsor: University Hospital, Akershus (Academic / non-profit / other)
Intervention(s): Nicotinamide Riboside, Mind-Body Reprocessing Therapy, Care As Usual
Start: Jan 2023  |  Primary completion: Sep 2024  |  Enrollment: 310 (actual)
Record last updated: Aug 2026

Long COVID, also referred to as post-acute sequela of COVID-19 (PASC), is present in a substantial number of individuals, and treatment for this is warranted. Two different hypothetical models of Long COVID suggest attenuated mitochondrial energy production and functional brain alterations associated with psychosocial load, respectively, to be key mechanisms in the underlying pathophysiology.

View on ClinicalTrials.gov ↗
CompletedPhase 2 NCT05747534
Sponsor: Massachusetts General Hospital (Academic / non-profit / other)
Intervention(s): Larazotide Acetate
Start: May 2023  |  Primary completion: Jun 2026  |  Enrollment: 107 (actual)
Record last updated: Aug 2026

The primary objective of this study is to evaluate the safety and efficacy of Larazotide (AT1001) versus placebo in children and adults 7 to ≤50 years of age who present with symptoms of Long COVID in the presence of SARS-CoV-2 antigenemia. AT1001 (n=100) or placebo (n=50) will be administered orally four times a day (QID) for 21 days.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT05705193
Sponsor: UConn Health (Academic / non-profit / other)
Intervention(s): Neuroflex
Start: Apr 2023  |  Primary completion: Dec 2025  |  Enrollment: 39 (actual)
Record last updated: Aug 2026

This research is being done to collect preliminary data on the potential of computerized "brain-training" exercises for treating Long COVID symptoms in older adults. The investigators hypothesize that computerized brain-training will be an acceptable and feasible intervention for treating Long COVID symptoms in older adults.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT05965739
Sponsor: Duke University (Academic / non-profit / other)
Intervention(s): Brainhq/Active Comparator Activity, Brainhq, Pasc Core, Tdcs-Active
Start: Sep 2023  |  Primary completion: Sep 2024  |  Enrollment: 328 (actual)
Record last updated: Aug 2026

This platform protocol is designed to be flexible so that it is suitable for a wide range of settings within health care systems, for remote settings, and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT07745699
Sponsor: National University of Natural Medicine (Academic / non-profit / other)
Intervention(s): Ketogenic Metabolic Therapy, Lifestyle Intervention
Start: Dec 2024  |  Primary completion: Jun 2025  |  Enrollment: 11 (actual)
Record last updated: Aug 2026

The goal of this clinical trial is to learn if a 12-week ketogenic diet program combined with lifestyle strategies (called KMT-LS) is practical and acceptable as a fully remote intervention for adults with Long COVID who also have Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. (ME/CFS) and dysautonomia (problems with heart rate, blood pressure, or other automatic body functions).

View on ClinicalTrials.gov ↗
CompletedPhase 2 NCT06305780
Sponsor: Kanecia Obie Zimmerman (Academic / non-profit / other)
Intervention(s): IVIG (Intravenous Immunoglobulin), Ivabradine + Coordinated Care
Start: Mar 2024  |  Primary completion: Jul 2025  |  Enrollment: 381 (actual)
Record last updated: Aug 2026

This study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans.

View on ClinicalTrials.gov ↗
CompletedPhase 2 NCT06305793
Sponsor: Kanecia Obie Zimmerman (Academic / non-profit / other)
Start: May 2024  |  Primary completion: Mar 2026  |  Enrollment: 200 (actual)
Record last updated: Jul 2026

This study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans.

View on ClinicalTrials.gov ↗
CompletedPhase 3 NCT05524532
Sponsor: University of Mississippi Medical Center (Academic / non-profit / other)
Intervention(s): Immulina Tm
Start: Jul 2023  |  Primary completion: Jul 2025  |  Enrollment: 101 (actual)
Record last updated: Jul 2026

This is a multi-site study that will try to determine the effects of Immulina ™, a natural dietary supplement, on blood chemicals associated with inflammation that are often increased in patients with long COVID (also called PASC).

View on ClinicalTrials.gov ↗
CompletedPhase 2 NCT04924881
Sponsor: Chinese University of Hong Kong (Academic / non-profit / other)
Intervention(s): Covid Rehab Formula Granules
Start: Jul 2021  |  Primary completion: Oct 2022  |  Enrollment: 68 (actual)
Record last updated: Jul 2026

COVID-19 has spread rapidly and now affects all over the world. On 11 March 2020, coronavirus disease 2019 (COVID-19) was declared a global pandemic by the World Health Organization (WHO). Most of the infected people will develop mild to moderate illness, for example fever, cough, tiredness and joint pain etc.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT07711444
Sponsor: National Science and Technology Council, Taiwan (Other government)
Intervention(s): Eicosapentaenoic Acid, Specialized Pro-Resolving Lipid Mediator
Start: Jun 2024  |  Primary completion: Dec 2025  |  Enrollment: 54 (actual)
Record last updated: Jul 2026

Researchers conducted a 12-week, double-blind, randomized, placebo-controlled trial to assess the effectiveness of EPA or SPM treatments versus a placebo in managing Long COVID symptoms in adult patients. Researchers planned to enroll 240 eligible participants from various general and psychiatric hospitals in Taiwan.

View on ClinicalTrials.gov ↗
CompletedPhase 2 NCT06404112
Sponsor: Duke University (Academic / non-profit / other)
Start: Jul 2024  |  Primary completion: Feb 2026  |  Enrollment: 469 (actual)
Record last updated: Jul 2026

The platform protocol is designed to be flexible so that it is suitable for a range of study settings and intervention types. Therefore, the platform protocol provides a general protocol structure that can be shared by multiple interventions and allows comparative analysis across the interventions.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT06404060
Sponsor: Duke University (Academic / non-profit / other)
Start: Jul 2024  |  Primary completion: Mar 2026  |  Enrollment: 360 (actual)
Record last updated: Jul 2026

This is a platform protocol designed to be flexible so that it is suitable for a range of interventions and settings within diverse health care systems and community settings with incorporation into clinical COVID-19 management programs and treatment plans if results achieve key study outcomes.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT06586398
Sponsor: University of California, Los Angeles (Academic / non-profit / other)
Intervention(s): Rtms
Start: Jan 2025  |  Primary completion: Mar 2026  |  Enrollment: 10 (actual)
Record last updated: Jul 2026

This is a pilot randomized trial of rTMS for symptoms of fatigue and brain fog, and other neuropsychiatric symptoms of Long-COVID (Post-COVID, post-acute sequelae of COVID-19 infection, PASC). Twenty participants diagnosed with Long-COVID and recruited from the UCLA Long-COVID clinic will be randomized to receive active rTMS versus sham stimulation for 15 treatments followed by another 15 open-label rTMS treatments.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT07651371
Sponsor: Universidade do Estado do Pará (Academic / non-profit / other)
Intervention(s): Physical Rehabilitation, Treadmill Ergometer, Pulley
Start: Jan 2021  |  Primary completion: Dec 2023  |  Enrollment: 74 (actual)
Record last updated: Jun 2026

The objective of this clinical trial is to analyze the clinical, functional, and laboratory effects of a rehabilitation protocol designed for patients with long COVID; it may include any of the following: sex/gender, age groups, healthy volunteers. The main questions it aims to answer are: Does handgrip strength improve after the intervention? Does the 6-minute walk test improve after the intervention?

View on ClinicalTrials.gov ↗
CompletedPhase 2 NCT06404099
Sponsor: Duke University (Academic / non-profit / other)
Intervention(s): Modafinil, Solriamfetol
Start: Aug 2024  |  Primary completion: Mar 2026  |  Enrollment: 361 (actual)
Record last updated: Jun 2026

The platform protocol is designed to be flexible so that it is suitable for a range of study settings and intervention types. Therefore, the platform protocol provides a general protocol structure that can be shared by multiple interventions and allows comparative analysis across the interventions.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT05699538
Sponsor: VA Office of Research and Development (US federal agency)
Intervention(s): Minimal-Dose Home-Based Resistance Exercise
Start: Jul 2023  |  Primary completion: Jul 2025  |  Enrollment: 21 (actual)
Record last updated: May 2026

The overall goal of this project is to advance the understanding of underlying mechanisms impacting performance fatigability and perceived fatigability in Veterans with post-COVID-19 fatigue and explore the safety and feasibility of a home-based "minimal-dose" resistance exercise program in this population.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT06214455
Sponsor: Pacific Northwest University of Health Sciences (Academic / non-profit / other)
Intervention(s): Low Sugar Diet And 10-12 Hour Eating Window, Low Sugar Diet, 8 Hour Eating Window And Fasting
Start: Nov 2022  |  Primary completion: Jul 2024  |  Enrollment: 77 (actual)
Record last updated: May 2026

This cross-over study will assess a no added sugar diet, a restricted daily eating window, and one or two full day water fasts to determine if there is an effect on self-reported symptoms of Long Covid (PASC).

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT06476496
Sponsor: University of Washington (Academic / non-profit / other)
Intervention(s): Acupuncture
Start: Jun 2024  |  Primary completion: Mar 2025  |  Enrollment: 93 (actual)
Record last updated: May 2026

The goal of this preliminary study is to test methods and procedures to be used in a fully-powered trial to evaluate acupuncture treatment effectiveness. Specifically, we will test the feasibility of conducting a 2-arm randomized clinical trial for evaluating the effectiveness of acupuncture for pain in patients with long COVID.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT06503913
Sponsor: University of Salford (Academic / non-profit / other)
Intervention(s): Cognitive Muscular Therapy, Breathing Visualisation
Start: Aug 2024  |  Primary completion: Mar 2026  |  Enrollment: 18 (actual)
Record last updated: May 2026

The aim of the study is to test a treatment known as "Cognitive Muscular Therapy (CMT)" for reducing breathlessness and improving autonomic function in patients with long-COVID.

View on ClinicalTrials.gov ↗
CompletedPhase 2 NCT05204550
Sponsor: Murdoch Childrens Research Institute (Academic / non-profit / other)
Intervention(s): Unfractionated Heparin
Start: Jan 2023  |  Primary completion: Dec 2024  |  Enrollment: 506 (actual)
Record last updated: May 2026

Coronavirus-induced disease 2019 (COVID-19) is an infection caused by a virus whose full name is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This is a new and rapidly-spreading infectious disease which carries a significant risk of death, has brought massive economic impact globally and has proved hard to contain through public health measures.

View on ClinicalTrials.gov ↗
CompletedEarly Phase 1 NCT06223971
Sponsor: Johns Hopkins University (Academic / non-profit / other)
Intervention(s): [11C]Cppc Injection
Start: Aug 2024  |  Primary completion: Apr 2025  |  Enrollment: 6 (actual)
Record last updated: Apr 2026

The goal of this study is to evaluate the safety of using the \[5-cyano-N-(4-(4-\[11C\]Methylpiperazin-1-yl)-2-(Piperidin-1-yl)Phenyl)Furan-2-carboxamide\] (\[11C\]CPPC) radiotracer in positron emission tomography (PET) imaging of people with history of COVID-19 infection, with and without symptoms.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT05846126
Sponsor: Consorci Sanitari de Terrassa (Academic / non-profit / other)
Intervention(s): Rehabcovid_Telematic, Rehabcovid_Immersivevr
Start: May 2023  |  Primary completion: Dec 2024  |  Enrollment: 172 (actual)
Record last updated: Apr 2026

Although most infected people survive the infection, many have persistent sequelae or symptoms, which cause disability or decreased quality of life. The World Health Organization has called on countries to prioritize the rehabilitation of the consequences of COVID-19 in both the medium and long term, as this chronicity is expected to impact the health public and the economy in the coming years.

View on ClinicalTrials.gov ↗
CompletedPhase 3 NCT05890534
Sponsor: University of Zurich (Academic / non-profit / other)
Intervention(s): Pycnogenol®
Start: Jun 2023  |  Primary completion: Nov 2024  |  Enrollment: 153 (actual)
Record last updated: Apr 2026

To determine the effect of Pycnogenol® versus placebo on patient-reported health status in people with post COVID-19 condition.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT07553897
Sponsor: Tri-Service General Hospital (TSGH) (Academic / non-profit / other)
Intervention(s): Telehealth Exercise Training Program
Start: Oct 2021  |  Primary completion: Nov 2023  |  Enrollment: 120 (actual)
Record last updated: Apr 2026

Patients with long coronavirus disease (COVID-19) experience multisystem symptoms and reduced quality of life (QOL). Proactive interventions are needed to enhance health outcomes.To investigate the effects of a 12-week tele-exercise training program on long COVID symptoms, cardiorespiratory fitness, and QOL.

View on ClinicalTrials.gov ↗
CompletedPhase 3 NCT04510194
Sponsor: University of Minnesota (Academic / non-profit / other)
Intervention(s): Metformin, Fluvoxamine, Ivermectin
Start: Jan 2021  |  Primary completion: Dec 2022  |  Enrollment: 1323 (actual)
Record last updated: Apr 2026

1. The purpose of this trial is to conduct a 2x3 factorial randomized trials, which efficiently allows the parallel conduct of three randomized trials to understand whether metformin, ivermectin, or fluvoxamine, is superior to placebo for preventing Covid-19 disease progression in non-hospitalized adults with SARS- CoV-2 infection. 2.

View on ClinicalTrials.gov ↗
CompletedPhase 3 NCT06128967
Sponsor: Cardresearch (Academic / non-profit / other)
Intervention(s): Fluvoxamine Maleate 100 Mg, Metformin
Start: Oct 2023  |  Primary completion: Jul 2025  |  Enrollment: 399 (actual)
Record last updated: Apr 2026

IRB approval date 14-APR-2024 and public at https://plataformabrasil.saude.gov.br/login.jsf since IURB approval Long COVID is a multi-systemic condition comprising often severe and persistent symptoms (longer than 12 weeks) that follow a known episode of COVID-19 and cannot be explained by another medical condition.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT06503874
Sponsor: Shirley Ryan AbilityLab (Academic / non-profit / other)
Intervention(s): Attention Training, Music Group
Start: Mar 2024  |  Primary completion: Mar 2026  |  Enrollment: 58 (actual)
Record last updated: Apr 2026

This study is to find out if the Attention Processing Training program is a potential treatment for brain fog symptoms, reported by people with Long-Covid. Also investigating the feasibility of completing this program virtually.

View on ClinicalTrials.gov ↗
CompletedPhase 2 NCT05965726
Sponsor: Kanecia Obie Zimmerman (Academic / non-profit / other)
Start: Jul 2023  |  Primary completion: Dec 2024  |  Enrollment: 964 (actual)
Record last updated: Mar 2026

This is an appendix of master protocol (NCT05595369) designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans.

View on ClinicalTrials.gov ↗
CompletedPhase 4 NCT05212610
Sponsor: University of Michigan (Academic / non-profit / other)
Intervention(s): Pfizer-Biontech Mrna Covid-19 Vaccine, Moderna Mrna Covid-19 Vaccine
Start: Mar 2022  |  Primary completion: Mar 2025  |  Enrollment: 137 (actual)
Record last updated: Mar 2026

This study will evaluate the safety of administering an additional dose of an mRNA COVID-19 vaccine or mRNA bivalent COVID-19 booster vaccine to individuals who have had adverse reactions to a previous dose or administering an initial dose of an mRNA COVID-19 vaccine to individuals with a personal history of allergic reaction.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT07492953
Sponsor: National Defense Medical Center, Taiwan (Academic / non-profit / other)
Start: Dec 2023  |  Primary completion: Jun 2024  |  Enrollment: 10 (actual)
Record last updated: Mar 2026

The goal of this clinical trial is to learn whether enhanced external counterpulsation (EECP) therapy can improve cardiopulmonary function and symptoms in adults with long COVID. It will also evaluate the safety and feasibility of two different EECP treatment schedules.

View on ClinicalTrials.gov ↗
CompletedPhase 2 NCT06437223
Sponsor: Inflammx Therapeutics Inc (Industry)
Intervention(s): Tonabersat
Start: Mar 2024  |  Primary completion: Sep 2025  |  Enrollment: 16 (actual)
Record last updated: Mar 2026

The primary objective of this study is to evaluate the safety and efficacy of Xiflam versus Placebo in patients who present with signs and symptoms of Long COVID. Xiflam (n=10) or placebo (n=5) will be administered orally once a day (QD) for 12 weeks.

View on ClinicalTrials.gov ↗
CompletedPhase 2 NCT05513560
Sponsor: University Health Network, Toronto (Academic / non-profit / other)
Intervention(s): Ibudilast, Pentoxifylline
Start: May 2023  |  Primary completion: Mar 2025  |  Enrollment: 460 (actual)
Record last updated: Feb 2026

The researchers propose to develop a Canada-wide, adaptive randomized clinical platform trial to assess the effectiveness of various interventions in patients with lingering symptoms of COVID-19 ("Long COVID"). Participants will be randomized initially to 1 of 3 arms, including placebo (control) and 2 interventions.

View on ClinicalTrials.gov ↗
CompletedPhase 2 NCT06305806
Sponsor: Kanecia Obie Zimmerman (Academic / non-profit / other)
Intervention(s): Ivabradine, Coordinated Care
Start: Mar 2024  |  Primary completion: Oct 2025  |  Enrollment: 181 (actual)
Record last updated: Feb 2026

This study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans.

View on ClinicalTrials.gov ↗
CompletedPhase 4 NCT05911906
Sponsor: University of Derby (Academic / non-profit / other)
Intervention(s): Remdesivir
Start: Oct 2024  |  Primary completion: Sep 2025  |  Enrollment: 73 (actual)
Record last updated: Feb 2026

Following an infection with Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV2), one in ten people will experience persisting symptoms, or develop symptoms which can last for months and even years. These symptoms affect people in different ways and have been demonstrated to broadly impact physical, mental, and cognitive health. This is called Long COVID.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT07418567
Sponsor: Université de Sherbrooke (Academic / non-profit / other)
Intervention(s): Prolonged Fasting
Start: May 2025  |  Primary completion: Nov 2025  |  Enrollment: 25 (actual)
Record last updated: Feb 2026

Background Long COVID (LC) is a chronic multisystemic condition which substantially impact the quality of life. Despite the staggering burden of LC, there is still no effective treatment. Because fasting promotes anti-inflammatory and antioxidant responses, which are involved in the pathophysiology of LC, we hypothesized that it might improve daily functioning and health-related quality of life in patients with LC.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT07397130
Sponsor: RSUP Persahabatan (Academic / non-profit / other)
Intervention(s): Pressure Biofeedback Unit
Start: Jul 2024  |  Primary completion: Aug 2025  |  Enrollment: 80 (actual)
Record last updated: Feb 2026

COVID-19 is an infectious disease that can cause long-term health problems even after the acute infection has resolved. Many people who have recovered from COVID-19 continue to experience breathing difficulties, fatigue, and reduced physical capacity.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT06739668
Sponsor: Icahn School of Medicine at Mount Sinai (Academic / non-profit / other)
Intervention(s): Pascal Device
Start: Dec 2024  |  Primary completion: Dec 2025  |  Enrollment: 30 (actual)
Record last updated: Feb 2026

The purpose of this study is to assess the feasibility of an at-home MMT treatment in patients with cognitive dysfunction related to PASC, and to collect data on safety and efficacy to inform the design of larger clinical studies. A prospective randomized controlled study of 30 participants with PASC and moderate to severe cognitive dysfunction.

View on ClinicalTrials.gov ↗
CompletedPhase 3 NCT04591210
Sponsor: Ottawa Heart Institute Research Corporation (Academic / non-profit / other)
Intervention(s): Angiotensin Converting Enzyme Inhibitor, Angiotensin Ii Receptor Blockers
Start: Jan 2021  |  Primary completion: Dec 2024  |  Enrollment: 372 (actual)
Record last updated: Jan 2026

The COVID-RASi study is an international randomized clinical trial that will evaluate the potential benefit of angiotensin modulators on clinical outcomes, in COVID-19 patients.

View on ClinicalTrials.gov ↗
CompletedPhase 2 NCT06055244
Sponsor: Ohio State University (Academic / non-profit / other)
Intervention(s): Amantadine
Start: Dec 2023  |  Primary completion: Dec 2025  |  Enrollment: 64 (actual)
Record last updated: Jan 2026

This study will look at the effects of amantadine on cognitive function in persons with Long COVID. It will also collect specimens to study possible causes of cognitive symptoms in Long COVID, and whether any lab tests can predict who will respond better to amantadine.

View on ClinicalTrials.gov ↗
CompletedPhase 2 NCT06404086
Sponsor: Duke University (Academic / non-profit / other)
Start: Jul 2024  |  Primary completion: Dec 2025  |  Enrollment: 830 (actual)
Record last updated: Jan 2026

The platform protocol is designed to be flexible so that it is suitable for a range of study settings and intervention types. Therefore, the platform protocol provides a general protocol structure that can be shared by multiple interventions and allows comparative analysis across the interventions.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT06156202
Sponsor: University of Pennsylvania (Academic / non-profit / other)
Intervention(s): Comprehensive Rehabilitation
Start: Nov 2023  |  Primary completion: Nov 2025  |  Enrollment: 125 (actual)
Record last updated: Jan 2026

About 10-20% of persons who contract SARS CoV-2 will experience persistent post-acute sequelae of SARSCoV-2 infection (referred here as PASC).

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT06492590
Sponsor: Consorci Sanitari de Terrassa (Academic / non-profit / other)
Intervention(s): Multicomponent Intervention
Start: Jan 2025  |  Primary completion: Sep 2025  |  Enrollment: 74 (actual)
Record last updated: Jan 2026

The goal of this clinical trial is to assess the effectiveness of a multicomponent intervention in individuals with Long COVID. The main questions it aims to answer are: * Does the intervention increase quality of life, mental well-being, resilience, and physical condition in individuals with Long COVID? * Does the intervention decrease anxiety, depressed mood, and fatigue in individuals with Long COVID?

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT05675995
Sponsor: University of California, Davis (Academic / non-profit / other)
Intervention(s): Qigong
Start: Jan 2023  |  Primary completion: May 2024  |  Enrollment: 40 (actual)
Record last updated: Jan 2026

The purpose of this study is to conduct a pilot feasibility study of a combination of external and internal qigong on health-related quality of life in individuals with prolonged symptoms following COVID-19 infection.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT06330376
Sponsor: University of Minnesota (Academic / non-profit / other)
Intervention(s): Specific Db Program/Diaphragmatic Manipulation Program
Start: Mar 2024  |  Primary completion: Aug 2025  |  Enrollment: 16 (actual)
Record last updated: Jan 2026

Diaphragm is the principal muscle of inspiration. Diaphragmatic dysfunction is seen in many conditions including following intubation, lung disease, prolonged ventilation, neuromuscular disease, phrenic nerve injury.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT07190105
Sponsor: Leidos Life Sciences (Industry)
Intervention(s): Sonocea Sonic Augmentation Technology, Truvaga Electrical Vagus Nerve Stimulator
Start: Oct 2025  |  Primary completion: Dec 2025  |  Enrollment: 546 (actual)
Record last updated: Jan 2026

The purpose of this study is to explore whether two general wellness products, alone or combined, can support individuals experiencing Long COVID symptoms. Both wellness products stimulate the vagus nerve - a nerve that helps regulate stress, relaxation, mood, breathing, heart rate, inflammation, and digestion.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT06189066
Sponsor: SecondWave Systems Inc. (Industry)
Intervention(s): Splenic Ultrasound
Start: Jan 2024  |  Primary completion: Jul 2024  |  Enrollment: 15 (actual)
Record last updated: Jan 2026

The research objective is to assess the safety and potential efficacy of spleen ultrasound stimulation as an intervention for Long COVID in a pilot study.

View on ClinicalTrials.gov ↗
CompletedPhase 2 NCT05999435
Sponsor: Laurent Pharmaceuticals Inc. (Industry)
Intervention(s): Lau-7B For 3 Cycles
Start: Nov 2023  |  Primary completion: Aug 2024  |  Enrollment: 272 (actual)
Record last updated: Jan 2026

ESSOR is a double-blind, placebo-controlled study of the orally-administered antiviral and inflammation-controlling LAU-7b for the treatment of adults with Long COVID and moderate to severe symptoms.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT06974058
Sponsor: Liaquat University of Medical & Health Sciences (Academic / non-profit / other)
Intervention(s): Nasafytol®
Start: Jul 2025  |  Primary completion: Nov 2025  |  Enrollment: 15 (actual)
Record last updated: Dec 2025

This pragmatic clinical study aims to evaluate the efficacy and tolerance of a combined quercetin/curcumin supplement in adults experiencing mild to moderate symptoms of Long COVID-19. Participants will receive the combined quercetin/curcumin supplement for 2 months.

View on ClinicalTrials.gov ↗
CompletedPhase 2 NCT05595369
Sponsor: Kanecia Obie Zimmerman (Academic / non-profit / other)
Start: Jul 2023  |  Primary completion: Aug 2024  |  Enrollment: 963 (actual)
Record last updated: Dec 2025

This study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT06404047
Sponsor: Duke University (Academic / non-profit / other)
Start: Jul 2024  |  Primary completion: Oct 2025  |  Enrollment: 660 (actual)
Record last updated: Nov 2025

This is a platform protocol designed to be flexible so that it is suitable for a range of interventions and settings within diverse health care systems and community settings with incorporation into clinical COVID-19 management programs and treatment plans if results achieve key study outcomes.

View on ClinicalTrials.gov ↗
CompletedPhase 2 NCT06253806
Sponsor: Washington University School of Medicine (Academic / non-profit / other)
Intervention(s): Stellate Ganglion Block
Start: Oct 2023  |  Primary completion: Sep 2024  |  Enrollment: 48 (actual)
Record last updated: Nov 2025

Chronic olfactory dysfunction, both hyposmia and parosmia, from the COVID-19 pandemic is a growing public health crisis with up to 1.2 million people in the United States affected. Olfactory dysfunction impacts one's quality of life significantly by decreasing the enjoyment of foods, creating environmental safety concerns, and affecting one's ability to perform certain jobs.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT06840873
Sponsor: Shang-Lin Chiang (Academic / non-profit / other)
Intervention(s): Wearable Device, Healthy Consulation
Start: Nov 2023  |  Primary completion: Jun 2024  |  Enrollment: 68 (actual)
Record last updated: Oct 2025

Long COVID can cause a decline in cardiorespiratory fitness, resulting in fatigue and negative impacts on individuals' quality of life (QoL), particularly in nurses who play a crucial role in public health. Combining with reduced cardiorespiratory fitness and suffering from a spectrum of long-COVID symptoms might substantially exaggertate fatigue, perceived stress, and reduce willingness to work for hospital nurses.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT07184398
Sponsor: Universidad Libre seccional Cali (Academic / non-profit / other)
Intervention(s): Intervention With Consolidated Cysteine (Immunocal) 20 G Per Day, Cognitive Rehabilitation Workshops
Start: Jul 2024  |  Primary completion: Sep 2024  |  Enrollment: 120 (actual)
Record last updated: Sep 2025

Abstract Background: Post-COVID-19 cognitive impairment (PCCI), characterized by deficits in attention, memory, and executive functioning, remains a major challenge among patients with long COVID. Oxidative stress is a key contributor to this condition. Cysteine-rich whey protein isolate (CRWPI), such as Immunocal®, enhances intracellular glutathione production and may offer neuroprotective benefits.

View on ClinicalTrials.gov ↗
CompletedPhase 2 NCT05576662
Sponsor: Stanford University (Academic / non-profit / other)
Start: Nov 2022  |  Primary completion: Aug 2023  |  Enrollment: 168 (actual)
Record last updated: Sep 2025

The purpose of this study is to compare whether being treated with nirmatrelvir plus ritonavir for 15 days works better than being treated with placebo plus ritonavir to reduce severe symptoms of Long Covid. Participants will have 5 planned visits to the study clinic over 15 weeks and will take the drug (or placebo) for the first 15 days.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT06620406
Sponsor: Columbia University (Academic / non-profit / other)
Intervention(s): Synbiotic Ivs-1, Maltodextrin
Start: Dec 2024  |  Primary completion: Aug 2025  |  Enrollment: 36 (actual)
Record last updated: Aug 2025

Gut microbiome dysbiosis has been noted in patients with Post-acute sequelae (PASC) of Severe Acute Respiratory Syndrome-CoronaVirus -2 (SARS-CoV-2). A study performed at Columbia found that plasma levels of the short chain fatty acid (SCFA), butyric acid, remained lower in people with Neuropsychiatric PASC (NP-PASC) than in people with PASC after SAR-CoV-2 infection.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT05836402
Sponsor: University of Southern California (Academic / non-profit / other)
Intervention(s): Low Carbohydrate Diet Intervention
Start: Sep 2023  |  Primary completion: Aug 2025  |  Enrollment: 14 (actual)
Record last updated: Aug 2025

Rationale: Hyper-inflammatory responses seen in acute COVID-19 are also a feature of long covid, a condition of long-term consequences that are persisting or appearing after initial infection and recovery from acute COVID-19. Long-standing, often disabling symptoms are common in long covid and can be highly varied.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT04828668
Sponsor: Endourage, LLC (Industry)
Intervention(s): Targeted Wellness Formula C™ Sublingual Drops - 1200Mg - 30 Ml
Start: Apr 2021  |  Primary completion: Jan 2022  |  Enrollment: 32 (actual)
Record last updated: Aug 2025

This study will explore the contribution of CBD oral drops in persons experiencing symptoms of Post Acute COVID Syndrome or "PACS".

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT05965752
Sponsor: Duke University (Academic / non-profit / other)
Intervention(s): Brainhq/Active Comparator Activity, Brainhq, Pasc Core, Tdcs-Active
Start: Sep 2023  |  Primary completion: Jun 2024  |  Enrollment: 328 (actual)
Record last updated: Jul 2025

This platform protocol is designed to be flexible so that it is suitable for a wide range of settings within health care systems, for remote settings, and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT06933017
Sponsor: Universitair Ziekenhuis Brussel (Academic / non-profit / other)
Intervention(s): Portable Mask For Respiratory Gas Analysis, Cardio-Pulmonary Exercise Test
Start: Mar 2025  |  Primary completion: Jul 2025  |  Enrollment: 25 (actual)
Record last updated: Jul 2025

This study aims to evaluate exercise capacity and identify causes of Post-Exertional Symptom Exacerbation (PESE) in individuals with Long COVID. The investigators will compare the effectiveness of the Two-Day 6-Minute Incremental Step Test (6MIST) and the Cardiopulmonary Exercise Test (CPET) in detecting PESE.

View on ClinicalTrials.gov ↗
CompletedPhase 1 NCT05857124
Sponsor: Vielight Inc. (Industry)
Intervention(s): Vielight Neuro Rx Gamma Active Device
Start: Apr 2023  |  Primary completion: Sep 2024  |  Enrollment: 36 (actual)
Record last updated: Jun 2025

Some people who have been infected with the virus that causes COVID-19 can experience long-term effects from their infection, known as post COVID-19 conditions (PCC) or long COVID1. The medical circles often describe it as post-acute sequelae of Covid-19 (PASC). People with post-COVID conditions can have a wide range of symptoms that can last more than four weeks or even months after infection.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT05894629
Sponsor: University of Valladolid (Academic / non-profit / other)
Intervention(s): Active Comparator: Usual Treatment
Start: Feb 2023  |  Primary completion: Jun 2023  |  Enrollment: 89 (actual)
Record last updated: Jun 2025

Justification: among the sequelae of Covid-19 in clinical practice we frequently find persistent neuromusculoskeletal pain. Previous studies carried out by this research group and in the scientific literature have shown that "Pain Neuroscience Education" (PNE) and Therapeutic Exercise (TE) constitute an effective care strategy in the treatment of persistent pain.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT06952127
Sponsor: Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec (Academic / non-profit / other)
Intervention(s): Rehabilitation Program
Start: Apr 2023  |  Primary completion: Mar 2024  |  Enrollment: 22 (actual)
Record last updated: Apr 2025

The goal of this study pilot randomized controlled study is to evaluate the feasibility of the study procedures and to compare the preliminary efficacy of a rehabilitation program given in a "remote" (telerehabilitation) or "face-to-face" model for adult patients who had confirmed SARS-CoV-2 infection and still have symptoms after eight weeks of infection.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT05922865
Sponsor: Shang-Lin Chiang (Academic / non-profit / other)
Intervention(s): Kneesup Smart Knee Assistive Device + Kneesup Care App, Healthy Consulation
Start: Jul 2023  |  Primary completion: Feb 2024  |  Enrollment: 120 (actual)
Record last updated: Apr 2025

The coronavirus (COVID -19) has rapidly turned into a global pandemic. For patients diagnosed with COVID-19, it caused severe damage in the upper respiratory system and systemic complications, including the cardiovascular, mental, nervous, and musculoskeletal system. Previous research has indicated that these subsequent sequelae can reduce quality of life.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT05633472
Sponsor: China Medical University Hospital (Academic / non-profit / other)
Intervention(s): Vitamin D
Start: Oct 2022  |  Primary completion: Aug 2024  |  Enrollment: 33 (actual)
Record last updated: Apr 2025

A double-blind study to evaluate the role of human microbiome and vitamin D in the development of long COVID and PACS in children.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT05453201
Sponsor: VA Office of Research and Development (US federal agency)
Intervention(s): Long Covid Coping And Recovery (Lccr) Intervention
Start: Oct 2022  |  Primary completion: Feb 2024  |  Enrollment: 22 (actual)
Record last updated: Apr 2025

Post-Acute COVID-19 Syndrome (PACS), colloquially known as Long COVID, is a prevalent phenomenon that affects thousands of Veterans in VA care.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT05172206
Sponsor: Schön Klinik Berchtesgadener Land (Academic / non-profit / other)
Intervention(s): Symptom-Focused Rehabilitation
Start: May 2022  |  Primary completion: Jan 2024  |  Enrollment: 132 (actual)
Record last updated: Mar 2025

Inpatient, multimodal rehabilitation represents one of the most important interventions in the disease management of post/long COVID. Different professional societies, including the German Society of Pneumology and the European Respiratory Society, recommend rehabilitation intervention to reduce the sequelae of COVID-19.

View on ClinicalTrials.gov ↗
CompletedPhase 1 NCT05638620
Sponsor: Jonathann Kuo, MD (Academic / non-profit / other)
Intervention(s): Stellate Ganglion Block With 0.5% Bupivacaine
Start: Jan 2023  |  Primary completion: Jun 2023  |  Enrollment: 20 (actual)
Record last updated: Mar 2025

The main purpose of this study is to gather data and assess changes in patient-reported outcomes with the stellate ganglion blocks as treatment for their sympathetically-mediated long COVID symptoms.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT05205460
Sponsor: Tri-Service General Hospital (TSGH) (Academic / non-profit / other)
Intervention(s): Home-Based Telerehabilitation
Start: Oct 2021  |  Primary completion: Apr 2023  |  Enrollment: 182 (actual)
Record last updated: Mar 2025

The aim of our study is to investigate the effectiveness of telerehabilitation in Post-COVID patients.

View on ClinicalTrials.gov ↗
CompletedPhase 3 NCT05795816
Sponsor: RDC Clinical Pty Ltd (Industry)
Intervention(s): Testofen, Microcrystalline Cellulose
Start: Oct 2023  |  Primary completion: Jan 2025  |  Enrollment: 150 (actual)
Record last updated: Mar 2025

This is a double blind, randomised, placebo-controlled trial to evaluate orally-dosed Testofen (a specialised extract of Trigonella foenum-graecum (Fenugreek) seed) compared to placebo on post COVID-19 symptoms in otherwise healthy participants 18 years and over.

View on ClinicalTrials.gov ↗
CompletedPhase 4 NCT05642923
Sponsor: ClinAmygate (Academic / non-profit / other)
Intervention(s): Synthetic Vitamin B1
Start: Jan 2023  |  Primary completion: Jun 2024  |  Enrollment: 528 (actual)
Record last updated: Mar 2025

Fatigue is recognized as one of the most commonly presented long-term complaints in individuals previously infected with SARS-CoV-2.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT05422924
Sponsor: University of Alberta (Academic / non-profit / other)
Intervention(s): Web-Based Platform.
Start: Aug 2023  |  Primary completion: Oct 2023  |  Enrollment: 45 (actual)
Record last updated: Mar 2025

Patients with COVID-19 may experience prolonged physical and psychological symptoms after weeks or months of the infection. This may be caused by a combination of factors including poor nutrition, low physical activity, and lack of emotional support. Leading to poor overall health and low quality of life.

View on ClinicalTrials.gov ↗
CompletedPhase 3 NCT03554265
Sponsor: The University of Texas Medical Branch, Galveston (Academic / non-profit / other)
Intervention(s): Somatropin
Start: Aug 2018  |  Primary completion: Oct 2023  |  Enrollment: 72 (actual)
Record last updated: Mar 2025

Patients with a history of mild traumatic brain injury (mTBI) or post acute sequelae of SARS-CoV-2 (PASC) and abnormal growth hormone secretion, as measured by glucagon stimulation test, will be treated with replacement growth hormone therapy for a period of 6 months (mTBI) or 9 months (PASC).

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT04900961
Sponsor: NHS Greater Glasgow and Clyde (Academic / non-profit / other)
Intervention(s): Resistance Exercise
Start: Jun 2021  |  Primary completion: Aug 2024  |  Enrollment: 233 (actual)
Record last updated: Feb 2025

Many people have long-lasting symptoms after COVID-19, such as breathlessness, fatigue and chest pain. So far, research studies of treatments for COVID-19 have focused on the life-threatening acute illness; few studies look at treatments to improve long-term health after COVID-19. COVID-19, particularly when this requires a hospital admission, can lead to weight loss and muscle wasting, contributing to worse outcomes.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT06726772
Sponsor: Cantonal Hospital of St. Gallen (Academic / non-profit / other)
Intervention(s): Group Psychotherapy
Start: Nov 2021  |  Primary completion: Jan 2024  |  Enrollment: 50 (actual)
Record last updated: Feb 2025

The aim of the present study was to establish a single-arm group psychotherapy and to evaluate its clinical effectiveness in long COVID patients.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT05139979
Sponsor: Beth Israel Deaconess Medical Center (Academic / non-profit / other)
Intervention(s): Breathing And Wellness Webinar, Routine Daily Activity
Start: Sep 2021  |  Primary completion: Feb 2024  |  Enrollment: 189 (actual)
Record last updated: Feb 2025

This study aims to assess the impact of brief digitally delivered breathing practice and guided meditation on post-Covid physical and mental symptoms in Long Covid Patients.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT05840237
Sponsor: Terra Biological LLC (Industry)
Intervention(s): Anhydrous Enol-Oxaloacetate, A "Medical Food", White Rice Flour
Start: Jun 2023  |  Primary completion: Jan 2025  |  Enrollment: 70 (actual)
Record last updated: Feb 2025

Following acute COVID-19, some patients develop a group of debilitating symptoms that include fatigue, orthostatic intolerance, difficulty with attention and concentration (often called "brain fog"), myalgias and disrupted sleep. The term Long COVID is used to describe these symptoms after the initial viral infection has passed.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT05817006
Sponsor: Samara State Medical University (Academic / non-profit / other)
Intervention(s): Device
Start: Apr 2023  |  Primary completion: Apr 2024  |  Enrollment: 88 (actual)
Record last updated: Jan 2025

During the pandemic of the new coronavirus infection COVID-19 in the world community, in the Russian Federation, in particular in the Samara region throughout the pandemic period from the end of 2019, when the first outbreak of a new coronavirus infection occurred in Wuhan (Hubei Province) in the People's Republic of China, the main focus on prevention (development of modern vaccines), diagnosis, treatment and further rehabilitation was done on the adult population.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT05676047
Sponsor: McMaster University (Academic / non-profit / other)
Intervention(s): Cognitive Rehabilitation
Start: May 2023  |  Primary completion: Jan 2025  |  Enrollment: 100 (actual)
Record last updated: Jan 2025

The investigators are comparing two different methods for helping adults with Long Coronavirus (COVID) also known as Post-Coronavirus Syndrome or Post-Coronavirus Condition manage everyday cognitive challenges. Cognitive rehabilitation is a type of therapy that helps people who have challenges with everyday thinking because of a brain injury.

View on ClinicalTrials.gov ↗
CompletedPhase 2 NCT06316843
Sponsor: Bateman Horne Center (Academic / non-profit / other)
Intervention(s): Valacyclovir Celecoxib Dose 1, Valacyclovir Celecoxib Dose 2
Start: Oct 2023  |  Primary completion: Oct 2024  |  Enrollment: 59 (actual)
Record last updated: Jan 2025

To explore the safety and efficacy of daily doses of celecoxib + valacyclovir in the treatment of patients with prolonged symptoms caused by COVID-19.

View on ClinicalTrials.gov ↗
CompletedPhase 2 NCT05592418
Sponsor: AIM ImmunoTech Inc. (Industry)
Intervention(s): Rintatolimod
Start: Jun 2023  |  Primary completion: Nov 2023  |  Enrollment: 80 (actual)
Record last updated: Jan 2025

The purpose of this study is to assess the efficacy and safety of Ampligen® administered twice weekly by intravenous (IV) infusions in subjects experiencing the Post-COVID Condition of fatigue.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT06091293
Sponsor: University of Colorado, Denver (Academic / non-profit / other)
Intervention(s): Narrative Intervention For Long Covid-19
Start: Oct 2022  |  Primary completion: Dec 2022  |  Enrollment: 12 (actual)
Record last updated: Dec 2024

This T1 proof of concept trial is designed to test the Narrative Intervention for Long COVID-19 intervention.

View on ClinicalTrials.gov ↗
CompletedPhase 2 NCT05823896
Sponsor: Karolinska Institutet (Academic / non-profit / other)
Start: May 2023  |  Primary completion: Nov 2024  |  Enrollment: 219 (actual)
Record last updated: Dec 2024

The purpose of this study is to investigate the efficacy of orally administered nirmatrelvir/ritonavir compared with placebo/ritonavir to improve quality of life in non-hospitalized adult participants suffering from post-acute COVID-19 syndrome.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT06492577
Sponsor: Spitalul Clinic de Boli Infecțioase și Pneumoftiziologie Dr. Victor Babeș Timișoara (Other government)
Intervention(s): Pulmonary Rehabilitation Protocol, Progressive Muscle Relaxation Protocol
Start: Jul 2024  |  Primary completion: Oct 2024  |  Enrollment: 61 (actual)
Record last updated: Dec 2024

Our study aimed to evaluate the effectiveness of a 21-day program combining pulmonary rehabilitation (PR) with progressive muscle relaxation (PMR) in patients experiencing long-term symptoms of COVID-19. Participants with persistent symptoms will be randomly assigned to either a PR group or a PR combined with PMR group.

View on ClinicalTrials.gov ↗
CompletedPhase 2 NCT05668091
Sponsor: Harlan M Krumholz (Academic / non-profit / other)
Start: Apr 2023  |  Primary completion: Apr 2024  |  Enrollment: 100 (actual)
Record last updated: Dec 2024

This decentralized trial is a Phase 2, 1:1 randomized, double-blind, superiority, placebo-controlled study in an anticipated 100 non-hospitalized highly symptomatic adult participants with long COVID. It seeks to determine the efficacy, safety, and tolerability of 15 days of Paxlovid (nirmatrelvir/ritonavir), an anti-viral agent, compared with placebo plus ritonavir.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT05298878
Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre (Academic / non-profit / other)
Intervention(s): Intervention Group: Virtual Home-Based Rehabilitation Plus Usual Outpatient Care
Start: Aug 2022  |  Primary completion: Sep 2023  |  Enrollment: 132 (actual)
Record last updated: Nov 2024

The purpose of this study is to investigate whether a timely, virtual home-based physical rehabilitation program for patients living with long COVID can improve functional mobility compared to usual care.

View on ClinicalTrials.gov ↗
CompletedPhase 2 NCT05472090
Sponsor: Tonix Pharmaceuticals, Inc. (Industry)
Intervention(s): Tnx-102 Sl
Start: Aug 2022  |  Primary completion: Jul 2023  |  Enrollment: 63 (actual)
Record last updated: Nov 2024

This is a Phase 2, randomized, parallel-group, double-blind, placebo-controlled, 14-week study designed to evaluate the efficacy and safety of TNX-102 SL 5.6 mg (2 x 2.8 mg tablets) taken once daily at bedtime for the management of multi-site pain associated with Long COVID.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT05630040
Sponsor: Icahn School of Medicine at Mount Sinai (Academic / non-profit / other)
Intervention(s): Non-Invasive Vagus Nerve Stimulation
Start: Nov 2022  |  Primary completion: Oct 2024  |  Enrollment: 40 (actual)
Record last updated: Nov 2024

The goal of this proposed clinical case series is to evaluate the effect of a non-invasive vagus nerve stimulation paradigm on: 1) Symptom reporting via validated patient reported outcomes, and 2) objective clinical biomarkers of autonomic nervous system function. This will be a placebo controlled, randomized controlled trial with a crossover design built in.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT05035628
Sponsor: Louis Bherer (Academic / non-profit / other)
Intervention(s): Cardiopulmonary Exercise Training
Start: Sep 2021  |  Primary completion: May 2023  |  Enrollment: 40 (actual)
Record last updated: Nov 2024

The objective of this project is to assess the effects of a 2-month cardiopulmonary rehabilitation program on cardiorespiratory fitness in long COVID19 patients. Quality of life, functional capacity, functional respiratory capacity, inflammatory profile, coagulation markers, cognitive functions and brain O2 saturation will also be assessed before and after the exercise rehabilitation program.

View on ClinicalTrials.gov ↗
CompletedPhase 1 NCT06108297
Sponsor: State University of New York at Buffalo (Academic / non-profit / other)
Intervention(s): Lithium
Start: Oct 2023  |  Primary completion: Mar 2024  |  Enrollment: 5 (actual)
Record last updated: Oct 2024

This open-label study will assess if lithium dosages of 30-45mg/day are associated with greater symptomatic benefit than dosages of 10-15mg/day previously assessed among 50 patients with long COVID.

View on ClinicalTrials.gov ↗
CompletedPhase 2 NCT05212688
Sponsor: Royal Marsden NHS Foundation Trust (Academic / non-profit / other)
Intervention(s): Acupuncture
Start: Jul 2022  |  Primary completion: Sep 2024  |  Enrollment: 119 (actual)
Record last updated: Oct 2024

The Covid pandemic has left us with a significant number of people suffering from Long COVID, which is a clinical diagnosis of significant and varying ongoing symptoms at least 12 weeks following COVID-19 infection and characterised frequently by fatigue and breathlessness. Acupuncture has been shown to help breathlessness and fatigue in other conditions including in patients with cancer.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT05453175
Sponsor: University of Winchester (Academic / non-profit / other)
Intervention(s): Interrupting Sitting With Physical Activity
Start: Oct 2022  |  Primary completion: Jul 2024  |  Enrollment: 45 (actual)
Record last updated: Oct 2024

People who sit uninterrupted for prolonged periods time have been shown to have poorer cardiovascular health compared to those that regularly interrupt it (e.g. standing up and moving). Cognition and brain function has also been shown to be impaired following uninterrupted sitting.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT06064838
Sponsor: Guillermo Ceballos Reyes (Academic / non-profit / other)
Intervention(s): Flavonoids
Start: Aug 2023  |  Primary completion: Aug 2024  |  Enrollment: 46 (actual)
Record last updated: Oct 2024

The study use a triple blind, placebo-controlled design enrolling male and female subjects between 30-70 yo to evaluate the effect of daily consumption of a cacao supplement on inflammation, endothelial damage, handgrip strength, fatigue scale and quality of life.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT05244044
Sponsor: University Hospital, Antwerp (Academic / non-profit / other)
Intervention(s): Pulmonary Rehabilitation In Primary Care
Start: Apr 2022  |  Primary completion: Dec 2023  |  Enrollment: 76 (actual)
Record last updated: Oct 2024

In the PuRe COVID study (a randomized, controlled, multicenter, pragmatic trial) the investigators aim to assess the effect of a pulmonary rehabilitation program in primary care on exercise capacity (6MWT) and daily life physical activity in patients with long COVID.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT05356936
Sponsor: University Hospitals Cleveland Medical Center (Academic / non-profit / other)
Intervention(s): Vitamin K2, Vitamin D3
Start: Jun 2022  |  Primary completion: Apr 2024  |  Enrollment: 151 (actual)
Record last updated: Sep 2024

Participants are being asked to take part in this research study because they have had a previous diagnosis (at least 3 months ago) of COVID-19 and are experiencing persistent, recurrent or even new symptoms, i.e. post-acute sequelae of SARS-CoV-2 (PASC).

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT05389592
Sponsor: University of Sao Paulo (Academic / non-profit / other)
Intervention(s): Active Tdcs And Cognitive Training
Start: Jun 2022  |  Primary completion: Nov 2022  |  Enrollment: 60 (actual)
Record last updated: Aug 2024

After almost 2 years of pandemic, the consequences of the post-COVID syndrome, or PASC (Post Acute-Sequelae of Sars-CoV-2), have become a major challenge in the management of affected patients, generating costs for health services. and insecurity regarding treatments for the sequelae, given the complex and still poorly understood pathophysiology of COVID-19.

View on ClinicalTrials.gov ↗
CompletedPhase 2 NCT04842448
Sponsor: Karolinska University Hospital (Academic / non-profit / other)
Start: Sep 2021  |  Primary completion: Sep 2023  |  Enrollment: 80 (actual)
Record last updated: Aug 2024

Long COVID Syndrome (Long COVID), Post Acute COVID-19 Syndrome (PACS) or Post COVID-19 Syndrome (PCS) is defined as 'signs and symptoms that develop during or following an infection consistent with COVID-19, continue for more than 12 weeks and are not explained by an alternative diagnosis'.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT06535165
Sponsor: Catholic University of the Sacred Heart (Academic / non-profit / other)
Intervention(s): Red Beetroot Juice
Start: Mar 2021  |  Primary completion: Jul 2021  |  Enrollment: 31 (actual)
Record last updated: Aug 2024

Red beetroot juice may have positive effects on multiple pathways involved in long COVID. The aim of this pilot study was to explore the impact of beetroot juice supplementation on physical function, gut microbiota, and systemic inflammation in adults with long-COVID.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT05200858
Sponsor: Baylor College of Medicine (Academic / non-profit / other)
Intervention(s): Tens - High-Dose, Tens - Low-Dose
Start: Mar 2022  |  Primary completion: Oct 2023  |  Enrollment: 30 (actual)
Record last updated: Jul 2024

The purpose of the pilot study is to examine acceptability and proof of concept effectiveness of a wireless TENS technology to address PASC associated FM. Sample size (n=30) is convenient and designed to explore acceptability and feasibility. Participants, who satisfy the inclusion and exclusion criteria and sign the informed consent form will be randomly assigned with ratio of 1:1 into two groups.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT06054438
Sponsor: The University of Hong Kong (Academic / non-profit / other)
Intervention(s): Chinese Medicine Nutritional Supplement Cs4
Start: Apr 2023  |  Primary completion: Mar 2024  |  Enrollment: 110 (actual)
Record last updated: Jul 2024

Cordyceps is a medicinal Chinese medicine. The benefits of cordyceps-related therapeutic action have been studied due to its anti-inflammation and immunomodulation features. Thus, Cordyceps may have efficacy against health problems in the post-COVID era. the Cs4 is a Chinese medicine nutritional supplement fermented by Cordyceps.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT05566379
Sponsor: University of California, Los Angeles (Academic / non-profit / other)
Intervention(s): Mindfulness - Mindful Awareness Practices
Start: Feb 2023  |  Primary completion: Jul 2023  |  Enrollment: 20 (actual)
Record last updated: Jun 2024

The current pilot study will recruit participants experiencing new, returning, or ongoing symptoms related to COVID-19 illness for at least four weeks after being first infected with SARS-CoV-2.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT06172803
Sponsor: Columbia University (Academic / non-profit / other)
Intervention(s): Restoring Energy With Sub-Symptom Threshold Aerobic Rehabilitation Exercise, Light Stretching/Breathing Exercises
Start: Oct 2023  |  Primary completion: Jan 2024  |  Enrollment: 4 (actual)
Record last updated: Jun 2024

The overall goal of this study is to find out if rehabilitation exercise can help people who have long COVID. Participants will be randomized by chance to receive either aerobic exercise or breathing exercise (combined with stretches).

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT06251011
Sponsor: Chulabhorn Hospital (Academic / non-profit / other)
Intervention(s): Exercise Training
Start: Feb 2024  |  Primary completion: Jun 2024  |  Enrollment: 32 (actual)
Record last updated: Jun 2024

This study aims to evaluate the effects of Physiotherapy Via Video Calls on Cardiopulmonary Functions, Physical Function, Cognitive Function, Activity Daily Livings, and Quality of Life in Patients With COVID-19.

View on ClinicalTrials.gov ↗
CompletedPhase 2 NCT04944121
Sponsor: Resolve Therapeutics (Industry)
Intervention(s): Rslv-132
Start: Jun 2021  |  Primary completion: Oct 2023  |  Enrollment: 112 (actual)
Record last updated: May 2024

The purpose of this study is to assess the efficacy (decrease in profound fatigue), safety and pharmacokinetics of RSLV-132 in subjects with long Corona Virus (COVID) syndome.

View on ClinicalTrials.gov ↗
CompletedPhase 2 NCT05497089
Sponsor: GeNeuro SA (Industry)
Intervention(s): Temelimab 54Mg/Kg
Start: Aug 2022  |  Primary completion: May 2024  |  Enrollment: 203 (actual)
Record last updated: May 2024

This study is a Phase 2, 24-week, randomized, prospective, double-blind, multicenter study in patients experiencing neuropsychiatric symptoms and functional impairment in the course of PASC.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT05793736
Sponsor: University of Cagliari (Academic / non-profit / other)
Intervention(s): Biofeedback Training, Treatment As Usual
Start: Feb 2023  |  Primary completion: Oct 2023  |  Enrollment: 17 (actual)
Record last updated: May 2024

Biofeedback equipment is classified by the Food and Drug Administration (FDA) as medical device class II and this type of equipment/treatment has shown evidence regarding stress management in post-Covid-19 syndrome.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT05697042
Sponsor: University of Colorado, Denver (Academic / non-profit / other)
Intervention(s): My-Skills For Long Covid
Start: Feb 2023  |  Primary completion: Dec 2023  |  Enrollment: 16 (actual)
Record last updated: May 2024

Long COVID patients experience high symptom burden for many months after initial infection of the COVID-19 virus. This study will investigate a mobile intervention Merging Yoga and Self-Management Skills (MY-Skills Mobile) as a complementary therapy for fatigue, pain, mood and quality of life in long COVID patients at the UCHealth Center for Integrative Medicine.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT05254301
Sponsor: Universitair Ziekenhuis Brussel (Academic / non-profit / other)
Intervention(s): Intervention Group
Start: Apr 2022  |  Primary completion: Jan 2024  |  Enrollment: 65 (actual)
Record last updated: May 2024

Long COVID is a new phenomenon, in which individuals who experienced a SARS-CoV-2 infection still experience one or more symptoms, such as exercise intolerance, fatigue and/or muscle pains in addition to other COVID-related symptoms, weeks to months after initial infection.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT06379737
Sponsor: Padua University General Hospital (Academic / non-profit / other)
Intervention(s): Multi-Systemic Rehabilitation
Start: Jan 2023  |  Primary completion: Dec 2023  |  Enrollment: 72 (actual)
Record last updated: Apr 2024

This study aimed to evaluate the effectiveness of a multisystem rehabilitation program for Long Covid patients in two different settings. Design: Randomized controlled trial. Settings: Health resort and home-based.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT04751669
Sponsor: Fundació Institut Germans Trias i Pujol (Academic / non-profit / other)
Intervention(s): Vitamin And Trace Elements
Start: Aug 2021  |  Primary completion: Oct 2023  |  Enrollment: 252 (actual)
Record last updated: Mar 2024

A double-blind, placebo-controlled, randomized clinical trial to assess efficacy of micronutrient dietary supplementation in reducing hospital admissions for COVID-19 and incidence of Long Covid. We want to assess the need for hospital admission for severe acute respiratory syndrome Corona Virus-2 (SARS-CoV-2) infection in outpatients diagnosed of COVID-19 disease, taking a micronutrient supplementation for 14 days.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT05848518
Sponsor: Campus docent Sant Joan de Déu-Universitat de Barcelona (Academic / non-profit / other)
Intervention(s): Rehabilitation Program
Start: May 2023  |  Primary completion: Sep 2023  |  Enrollment: 120 (actual)
Record last updated: Mar 2024

Many patients with COVID-19 present the so-called post-acute sequelae of COVID-19 such as fatigue, post-stress discomfort, dyspnea, headache, pain mental impairment, incapacity to perform daily physical tasks ant exercise intolerance.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT05601180
Sponsor: Beker Laboratories (Industry)
Intervention(s): Respicure®, Standard Of Care
Start: Oct 2022  |  Primary completion: Jan 2024  |  Enrollment: 402 (actual)
Record last updated: Mar 2024

Interventional, Prospective, National, Multicentre, Randomised, Open-label, Controlled Clinical Study Comparing Two Parallel Groups, One Control Arm (Standard Treatment) Versus Intervention Arm (Standard Treatment + Study Product) Evaluating the Efficacy of Respicure® 0.38% /0.38% (Resveratrol / Quercetin) Phytotherapy Product From BEKER Laboratories as an add-on Treatment in the Management of Respiratory Conditions Including Asthma (Partially Controlled),COPD (Stage A, B, C and D) and long COVID in Algerian Adult Patients .

View on ClinicalTrials.gov ↗
CompletedPhase 2 NCT05760092
Sponsor: University of Nove de Julho (Academic / non-profit / other)
Intervention(s): Institutional Standard Treatment For Xerostomia And Long Covid, Photobiomodulation Therapy
Start: Mar 2023  |  Primary completion: Feb 2024  |  Enrollment: 10 (actual)
Record last updated: Mar 2024

Coronavirus (COVID-19) is a newly emerging zoonotic agent that emerged in December 2019 in China (2019-nCoV) as a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV -2). Long COVID-19, or Post-Covid Syndrome or Long-term COVID-19, is a post-viral syndrome that persists after the acute infection has resolved. The most frequent symptoms of Lonf-term COVID are fatigue and dyspnea.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT06294756
Sponsor: University of Roma La Sapienza (Academic / non-profit / other)
Intervention(s): Inhalation Of Sulfurous Thermal Water, Inhalation Of Sterile Distilled Non-Pyrogenic Water
Start: May 2023  |  Primary completion: Aug 2023  |  Enrollment: 30 (actual)
Record last updated: Mar 2024

The goal of this double-blind, interventional, randomized case-control, pilot trial is to evaluate the effects of active sulfurous (STW) versus placebo (SDW) inhalations on blood test parameters, serum inflammatory cytokines, spirometry data, as well as qualitative and quantitative changes in the nasal microbiome of subjects affected by long Covid.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT06013072
Sponsor: University of Novi Sad, Faculty of Sport and Physical Education (Academic / non-profit / other)
Intervention(s): Dietary Supplement: Experimental
Start: Oct 2022  |  Primary completion: Dec 2023  |  Enrollment: 32 (actual)
Record last updated: Feb 2024

The goal of this randomized controlled double-blind parallel-group interventional trial is to evaluate the effects of of dietary supplementation with a pre-probiotic on patient- and clinician-reported outcomes, and brain tissue metabolism in patients with post-covid fatigue syndrome.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT05608629
Sponsor: Icahn School of Medicine at Mount Sinai (Academic / non-profit / other)
Intervention(s): Transcutaneous Non-Invasive Vagus Nerve Stimulation
Start: Jun 2022  |  Primary completion: Dec 2022  |  Enrollment: 17 (actual)
Record last updated: Jan 2024

Many patients do not recover following Covid infection. The resulting illness is called Long Covid. Because there is no agreed upon treatment for this ailment, the research team has decided to do an open label pilot study using non-invasive, transcutaneous stimulation of the auricular branch of the vagus nerve.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT05679505
Sponsor: Bahçeşehir University (Academic / non-profit / other)
Intervention(s): Auricular Transcutaneous Vagus Nerve Stimulation
Start: Oct 2022  |  Primary completion: Jan 2023  |  Enrollment: 40 (actual)
Record last updated: Jan 2024

The aim of this study is to increase parasympathetic activity and decrease the severity of symptoms by providing vagal stimulation with the t-VNS method in order to suppress the increased sympathetic activity in patients with prolonged Covid symptoms.The main question\[s\] it aims to answer are: Question 1:Is left ear transcutaneous vagus nerve stimulation effective in suppressing the symptoms of patients in Post Covid syndrome?

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT05770193
Sponsor: Cairo University (Academic / non-profit / other)
Intervention(s): Pursed Lip Breathing, Cognitive Behavior Therapy, Diaphragmatic Breathing Exercise, Kinesio Tape
Start: Mar 2023  |  Primary completion: Aug 2023  |  Enrollment: 60 (actual)
Record last updated: Dec 2023

According to WHO, current evidence suggests some people experience a variety of long-term effects after they recover from their initial illness. These effects are collectively known as post COVID-19 condition or "long COVID. While most people who develop COVID-19 fully recover, some people develop effects like fatigue, breathlessness, functional activities and cognitive dysfunction.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT05630378
Sponsor: Universität Duisburg-Essen (Academic / non-profit / other)
Intervention(s): Outpatient Clinic With Multimodal Integrative Medicine And Naturopathy For Post-Covid-19 Patients, Waiting Group
Start: May 2022  |  Primary completion: Feb 2023  |  Enrollment: 42 (actual)
Record last updated: Dec 2023

The study aims to identify whether a multimodal integrative naturopathy outpatient clinical concept can improve the symptoms of patients suffering from post-COVID-Syndrome. Main outcome is fatigue. The outpatient clinical programme consists of 11 weeks wherein patients visit the clinic one day per week.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT05080244
Sponsor: Centre de recherche du Centre hospitalier universitaire de Sherbrooke (Academic / non-profit / other)
Intervention(s): Probiotics
Start: Oct 2021  |  Primary completion: Dec 2022  |  Enrollment: 618 (actual)
Record last updated: Nov 2023

Probiotics may be considered as an option of treatment for long COVID since they have anti-viral effect, trigger immunomodulation and have low side-effects. This randomized controlled trial aims to reduce the number of patients with long COVID by 25% 90 days after the COVID-19 diagnosis by taking probiotics in a symptomatic population, self-caring at home.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT05630339
Sponsor: Coordinación de Investigación en Salud, Mexico (Other government)
Intervention(s): Magnesium Chloride, Vitamin D
Start: Jan 2022  |  Primary completion: May 2023  |  Enrollment: 150 (actual)
Record last updated: Sep 2023

The goal of this double-blind randomized controlled clinical trial is to determine the efficacy of the administration of magnesium chloride + vitamin D as an adjuvant in the treatment of post-Coronavirus Disease (COVID) syndrome.

View on ClinicalTrials.gov ↗
CompletedPhase 1 NCT04880161
Sponsor: Ampio Pharmaceuticals. Inc. (Industry)
Intervention(s): Ampion
Start: Jul 2021  |  Primary completion: Dec 2021  |  Enrollment: 32 (actual)
Record last updated: Sep 2023

This is a phase I study to evaluate the safety and efficacy of inhaled Ampion on patients with prolonged respiratory symptoms due to COVID-19 (Long COVID).

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT05961462
Sponsor: Guangdong Provincial People's Hospital (Academic / non-profit / other)
Intervention(s): Exercise Training
Start: Jan 2023  |  Primary completion: Jul 2023  |  Enrollment: 24 (actual)
Record last updated: Sep 2023

Effects of Exercise training on Patients With Long COVID-19, is a single-center, randomized, controlled trial designed to evaluate the effects of 4- week aerobic exercise administered to patients with long COVID-19 symptoms. The main outcome is cardiopulmonary fitness and long COVID-19 symptom improvement.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT05752331
Sponsor: Bournemouth University (Academic / non-profit / other)
Intervention(s): Physical Activity Behavioural Modification
Start: Nov 2022  |  Primary completion: May 2023  |  Enrollment: 32 (actual)
Record last updated: Aug 2023

This pilot RCT aims to assess whether a simple PA behavioural modification intervention can be delivered safely and feasibly to individuals with Long COVID suffering long standing symptoms with concerns regarding their ability to perform activities of daily living. Participants will be randomised to receive an 8-week physical activity behavioural modification intervention alongside usual care or usual care alone.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT05973136
Sponsor: Université de Sherbrooke (Academic / non-profit / other)
Intervention(s): Telerehabilitation Program Based On Cardiorespiratory Principles
Start: Apr 2022  |  Primary completion: Aug 2022  |  Enrollment: 7 (actual)
Record last updated: Aug 2023

Telerehabilitation is a great alternative to offering care during a global pandemic. 85% of patients with COVID-19 report persistent symptoms up to 8 months after the infection. There are no clear recommendations for post-covid rehabilitation.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT05631171
Sponsor: Adhera Health, Inc. (Industry)
Intervention(s): Adhera® Fatigue Digital Program
Start: Dec 2022  |  Primary completion: Jun 2023  |  Enrollment: 58 (actual)
Record last updated: Jul 2023

Adhera® Fatigue Digital Program (or AFDP) is a digital health program based on behavioral and emotional change techniques that provides personalized physical and emotional self-management support for patients with long COVID-related fatigue. The digital health solution is designed to be used for 3 months, and includes a mobile application and a smartwatch.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT05204511
Sponsor: University of Vienna (Academic / non-profit / other)
Intervention(s): Endurance Training, Concurrent Training
Start: Feb 2022  |  Primary completion: May 2023  |  Enrollment: 66 (actual)
Record last updated: Jul 2023

The current COVID-19 pandemic is the most severe health crisis of the 21st century. This is not only due to the deaths caused by the disease. People that were affected by COVID-19 and supposedly recovered may suffer from long lasting sequelae.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT05225220
Sponsor: Casa Colina Hospital and Centers for Healthcare (Academic / non-profit / other)
Intervention(s): Parasym Device
Start: Mar 2022  |  Primary completion: Jan 2023  |  Enrollment: 25 (actual)
Record last updated: Jul 2023

The purpose of this study is to investigate the effects of transcutaneous vagus nerve stimulation (t-VNS) on Long Covid symptoms in females and to identify factors influencing susceptibility and recovery-particularly in the cognitive domain, as over 80% of long-haulers experience "brain fog".

View on ClinicalTrials.gov ↗
CompletedPhase 2 NCT05445674
Sponsor: Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia (Academic / non-profit / other)
Intervention(s): Plasma Exchange Procedure
Start: Sep 2022  |  Primary completion: Jun 2023  |  Enrollment: 50 (actual)
Record last updated: Jun 2023

PAX is a prospective, randomized (1:1), double-blind, placebo-controlled study, that have as a objective to evaluate the safety and tolerability of plasma exchange (PE) in patients with Post Acute Covid-19 Syndrome (PCC) comparing to sham plasma exchange.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT05848401
Sponsor: Anxiety Relief Center (Academic / non-profit / other)
Intervention(s): Biosound Therapy System
Start: Apr 2021  |  Primary completion: Jan 2022  |  Enrollment: 13 (actual)
Record last updated: May 2023

This study aimed to explore the impact of the Biosound Therapy Systerm on long COVID symptoms while determining feasibility of a future full-scale Randomized Controlled Trial. It was hypothesized that Biosound treatment would significantly improve long COVID. The goal of this clinical trial is to learn about Biosound Therapy System's impact on long COVID symptoms.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT05196529
Sponsor: York University (Academic / non-profit / other)
Start: May 2022  |  Primary completion: Jan 2023  |  Enrollment: 40 (actual)
Record last updated: Apr 2023

Coronavirus-2019 (COVID-19) is a viral disease leading to respiratory dysfunction, but it may also affect the brain and result in the development of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). This may be the result of the COVID-19 virus infecting regions of the brain responsible for respiratory control.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT05531019
Sponsor: Fernando Saldarini (Academic / non-profit / other)
Intervention(s): Echinochrome A
Start: Sep 2021  |  Primary completion: Dec 2022  |  Enrollment: 54 (actual)
Record last updated: Feb 2023

The aim of this study is to assess the efficacy and efficiency of a nutraceutical from sea urchin eggs with Echinochrome A in the inflammation of tissues in subjects with long Corona Virus (COVID) syndome.

View on ClinicalTrials.gov ↗
CompletedPhase 2 NCT04997395
Sponsor: Bod Australia (Industry)
Intervention(s): Medicabilis Cannabis Sativa 50
Start: Apr 2022  |  Primary completion: Jan 2023  |  Enrollment: 12 (actual)
Record last updated: Jan 2023

This is an open label, phase 2 clinical trial to assess the feasibility of a cannabidiol (CBD) dominant medicinal cannabis for the treatment of Long COVID. The primary aim is to assess the feasibility of recruiting and retaining individuals diagnosed with Long COVID into a treatment trial of medicinal cannabis, as well as assessing the safety and tolerability of a dominant medicinal cannabis in this population.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT05279430
Sponsor: Fundación para la Investigación del Hospital Clínico de Valencia (Academic / non-profit / other)
Start: Jan 2022  |  Primary completion: Jul 2022  |  Enrollment: 26 (actual)
Record last updated: Dec 2022

Exercise intolerance and fatigue are the most common symptoms in patients with chronic COVID after hospital discharge. Muscle deconditioning, dysautonomia, and exercise hyperventilation have been proposed as potential mechanisms contributing to exercise functional capacity limitation in Long-COVID.

View on ClinicalTrials.gov ↗
CompletedPhase 2 NCT05152849
Sponsor: Axcella Health, Inc (Industry)
Intervention(s): Axa1125
Start: Dec 2021  |  Primary completion: Jun 2022  |  Enrollment: 41 (actual)
Record last updated: Oct 2022

This study will compare the effects of AXA1125, an orally active mixture of amino acids, compared to placebo, on improving muscle function (metabolism) following moderate exercise in subjects with fatigue-Predominant Post-Acute Sequelae of SARS-CoV-2 as well as the safety and tolerability of AXA1125. Subjects will take one dose of AXA1125 or a placebo twice daily for 28 days.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT05571852
Sponsor: Universidad Antonio de Nebrija (Academic / non-profit / other)
Intervention(s): Cognifit'S Cct Post Covid-19
Start: Dec 2021  |  Primary completion: Feb 2022  |  Enrollment: 73 (actual)
Record last updated: Oct 2022

This before-and-after study aims to evaluate the usefulness and efficacy of a personalized computerized cognitive training (CCT) to improve cognitive function among people with post-acute sequelae of COVID-19 (PASC).

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT05483829
Sponsor: Adhera Health, Inc. (Industry)
Intervention(s): Adhera® Fatigue For Long Covid Program
Start: Aug 2022  |  Primary completion: Aug 2022  |  Enrollment: 15 (actual)
Record last updated: Sep 2022

The AIDA feasibility study builds upon mental health and technology acceptance theoretical frameworks. It examines the feasibility of a mobile-based digital program to support patients with long covid affected by fatigue. The program Adhera ® Fatigue Self-management is adapted for long covid patients.

View on ClinicalTrials.gov ↗
CompletedPhase not applicable NCT04810065
Sponsor: University of Limerick (Academic / non-profit / other)
Intervention(s): Singstrong: Strong Lungs Through Song
Start: Mar 2021  |  Primary completion: Jul 2021  |  Enrollment: 30 (actual)
Record last updated: Sep 2021

Evidence is emerging that many individuals who recover from Covid-19 are experiencing a range of residual problems. These include fatigue, pain, reduced exercise tolerance and breathing issues. This study includes participants who are experiencing problems with their lungs such as breathing difficulties, shortness of breath, and/or reduced exercise tolerance.

View on ClinicalTrials.gov ↗

Suspended (3)

SuspendedPhase not applicable NCT07454395
Sponsor: Simon Fraser University (Academic / non-profit / other)
Intervention(s): Swimming, Cycling
Start: Feb 2026  |  Primary completion: Jan 2027  |  Enrollment: 50 (estimated)
Record last updated: Mar 2026

Individuals with ME/CFS experience profound exercise intolerance and post-exertional malaise. This remote (app-based) pilot study explores whether light, fully self-paced, swimming may be a tolerable form of movement for people with ME/CFS and related conditions, due to the distinct physiological effects of water immersion.

View on ClinicalTrials.gov ↗
SuspendedEarly Phase 1 NCT06171152
Sponsor: University of Chicago (Academic / non-profit / other)
Intervention(s): Liraglutide Pen Injector [Saxenda], Medication Diary
Start: Jan 2024  |  Primary completion: Jun 2027  |  Enrollment: 30 (estimated)
Record last updated: Mar 2026

This study is for people who have multiple sclerosis, acute leukemia (in remission), or long-COVID and a Body Mass Index over 27 and may struggle with cognitive issues such as remembering information, concentrating, or making decisions that affect everyday life.

View on ClinicalTrials.gov ↗
SuspendedPhase not applicable NCT05693064
Sponsor: Life University (Academic / non-profit / other)
Intervention(s): Chiropractic Adjustments
Start: Jan 2025  |  Primary completion: Jun 2025  |  Enrollment: 40 (estimated)
Record last updated: Aug 2024

The purpose of this waitlist-controlled, single-blind, one-way crossover, pilot trial is to evaluate the potential effects of \~8 weeks of chiropractic care on patient-reported fatigue and the autonomic nervous system in adults with long COVID.

View on ClinicalTrials.gov ↗

Terminated (10)

TerminatedPhase not applicable NCT05530317
Sponsor: University of California, San Francisco (Academic / non-profit / other)
Intervention(s): Cardiac Rehabilitation
Start: Dec 2022  |  Primary completion: Jul 2026  |  Enrollment: 13 (actual)
Record last updated: Aug 2026

The goal of this proof-of-concept clinical trial is to determine whether cardiac rehabilitation improves exercise capacity and chronotropic (heart rate) response to exercise among people with Long COVID.

View on ClinicalTrials.gov ↗
TerminatedPhase 3 NCT06524739
Sponsor: CSL Behring (Industry)
Intervention(s): Igpro20
Start: Aug 2024  |  Primary completion: Jun 2025  |  Enrollment: 16 (actual)
Record last updated: Apr 2026

This is a prospective, phase 3, multicenter, double-blind, randomized placebo-controlled study to investigate the efficacy, safety, and pharmacokinetics (PK) of repeat doses of IgPro20 in participants with post SARS-CoV-2 infection 2019 postural orthostatic tachycardia syndrome (post-Coronavirus Disease 2019 \[COVID-19\] POTS \[post-COVID-POTS\]).

View on ClinicalTrials.gov ↗
TerminatedPhase not applicable NCT05398692
Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (Academic / non-profit / other)
Intervention(s): On Site Exercise Rehabilitation
Start: Feb 2022  |  Primary completion: Dec 2023  |  Enrollment: 21 (actual)
Record last updated: Sep 2025

The purpose of the study is to assess the physiologic, immunologic, and mental health effects of an exercise and pulmonary rehabilitation program on patients with Long COVID-19 (LC).

View on ClinicalTrials.gov ↗
TerminatedEarly Phase 1 NCT05096884
Sponsor: Hackensack Meridian Health (Academic / non-profit / other)
Intervention(s): Metoprolol Succinate
Start: Mar 2022  |  Primary completion: Sep 2023  |  Enrollment: 14 (actual)
Record last updated: Dec 2024

Most patients with acute COVID-19 (Coronavirus 19) recover within weeks, however a significant number of individuals will develop the post-acute COVID 19 syndrome (PASC). As of July 2021, the post COVID syndrome qualifies as a disability under the Americans with Disabilities Act. The symptoms which comprise this condition are highly variable and often extraordinarily debilitating.

View on ClinicalTrials.gov ↗
TerminatedPhase 1 NCT05121766
Sponsor: Hackensack Meridian Health (Academic / non-profit / other)
Intervention(s): Omega-3
Start: Jan 2022  |  Primary completion: Apr 2023  |  Enrollment: 32 (actual)
Record last updated: Sep 2024

This is a two-arm, double blind randomized 12-week study to supplement omega-3 (Eicosapentaenoic acid - EPA + docosahexaenoic acid - DHA) among 100 adults (age 18+) who had coronavirus-19 (covid-19) and are experiencing possible after-effects from post-acute sequelae of covid-19 (also called post-covid syndrome or long covid syndrome).

View on ClinicalTrials.gov ↗
TerminatedPhase not applicable NCT05813899
Sponsor: Mackay Memorial Hospital (Academic / non-profit / other)
Intervention(s): Ps23 Heat-Treated
Start: Jan 2023  |  Primary completion: Dec 2023  |  Enrollment: 39 (actual)
Record last updated: Aug 2024

To evaluate whether probiotics PS23 can improve the symptoms of patients with long COVID-19 ; also to evaluate the effects on blood cortisol and inflammation-related indicators in patients.

View on ClinicalTrials.gov ↗
TerminatedPhase 4 NCT05597722
Sponsor: Eva Szigethy (Academic / non-profit / other)
Intervention(s): Digital Cognitive Behavioral Intervention-Rxwell, Amphetamine-Dextroamphetamine
Start: Apr 2023  |  Primary completion: May 2023  |  Enrollment: 7 (actual)
Record last updated: Jul 2024

This study will assess two options to help patients better manage the cognitive fog and emotional distress that may be associated with having Long-COVID. Long-COVID is post-COVID conditions or symptoms lasting more than four weeks after infection.

View on ClinicalTrials.gov ↗
TerminatedPhase not applicable NCT06113679
Sponsor: EmitBio Inc. (Industry)
Intervention(s): Rdx-19
Start: Oct 2023  |  Primary completion: May 2024  |  Enrollment: 41 (actual)
Record last updated: Jul 2024

Duration of Treatment: 7 days, 2 times per day. Following Randomization on Week 1 Day 1, Subjects will continue to have televisits and rate symptoms and upright activity weekly during a 5 week follow up. Subjects will be followed via in clinic visits at week 2/day 8 (+3/-0 days) and Week 6 / day 36, (+3/-3days).

View on ClinicalTrials.gov ↗
TerminatedPhase 3 NCT04695704
Sponsor: Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina (Academic / non-profit / other)
Intervention(s): Montelukast
Start: Aug 2021  |  Primary completion: Jul 2023  |  Enrollment: 86 (actual)
Record last updated: Jul 2024

Recently, a new clinical presentation called "long covid" has been reported, for patients with symptoms lasting for more than 4 weeks from the onset of the disease.

View on ClinicalTrials.gov ↗

Withdrawn (14)

WithdrawnPhase 3 NCT05858515
Sponsor: Vanderbilt University Medical Center (Academic / non-profit / other)
Intervention(s): Baricitinib 4 Mg
Start: Oct 2024  |  Primary completion: Dec 2027
Record last updated: Sep 2026

REVERSE-LC is a phase 3 trial of baricitinib versus placebo in adults with neurocognitive impairment (a form of Alzheimer's Disease and Related Dementias or ADRD) or cardiopulmonary symptoms due to Long COVID.

View on ClinicalTrials.gov ↗
WithdrawnPhase not applicable NCT07714889
Sponsor: Toivoa Inc (Industry)
Intervention(s): Rauha® Digital Therapeutic Platform
Start: Jul 2026  |  Primary completion: Sep 2026
Record last updated: Jul 2026

This study will evaluate Toivoa-004 as an experimental digital therapeutic for persons with Long COVID suffering from anxiety or depression. This study will evaluate the completion rates of the Toivoa-004 program and survey the user's experience upon completion. Changes in anxiety and depression scores will be monitored during the study.

View on ClinicalTrials.gov ↗
WithdrawnPhase not applicable NCT06082258
Sponsor: Assistance Publique - Hôpitaux de Paris (Academic / non-profit / other)
Intervention(s): Training In The Management Of Functional Disorders, Reimbursement Of 3 Long Consultations
Start: Nov 2024  |  Primary completion: Dec 2025
Record last updated: Jul 2026

Evaluation of the effectiveness of a training and support intervention for general practitioners treating patients with persistent symptoms after a COVID-19 episode on the patients'quality of life at 3 months.

View on ClinicalTrials.gov ↗
WithdrawnPhase not applicable NCT06637800
Sponsor: ExThera Medical Corporation (Industry)
Intervention(s): Seraph® 100 Microbind® Affinity Blood Filter
Start: Feb 2025  |  Primary completion: Apr 2025
Record last updated: Apr 2026

This study will use a prospective, open, single-arm design, in which a group of 100 patients with a diagnosis of prolonged COVID, previously selected according to inclusion and exclusion criteria, and who have undergone informed consent process and have signed the informed consent form, undergo two hemoperfusion procedures with the Seraph 100 filter, on consecutive days.

View on ClinicalTrials.gov ↗
WithdrawnPhase 2 NCT06234462
Sponsor: University of Texas Southwestern Medical Center (Academic / non-profit / other)
Intervention(s): Amantadine, Physical, Occupational, Speech Therapy, Provider Counseling, Medications For Symptoms Management
Start: Jun 2025  |  Primary completion: Sep 2025
Record last updated: Aug 2025

To decrease symptom burden, improve cognitive function, improve endurance, and decrease fatigue in subjects with post-acute sequelae of COVID-19 (PASC) or "long-hauler" COVID using amantadine. If amantadine use is determined to be efficacious in this population, the findings of this study will be used towards a subsequent randomized control trial.

View on ClinicalTrials.gov ↗
WithdrawnPhase not applicable NCT05467904
Sponsor: LUCINDA BATEMAN, MD (Academic / non-profit / other)
Intervention(s): Xltranplus, Xltran
Start: Aug 2024  |  Primary completion: May 2025
Record last updated: Jul 2025

This is a double-blind, randomized, placebo-controlled single-center clinical trial to explore the safety and efficacy of a full cannabis flower formulation, rich in cannabinoids and terpenes formulation, Xltran Plus™ and Xltran™, both compared to placebo for the treatment of Long COVID patients with prolonged symptoms caused by COVID-19.

View on ClinicalTrials.gov ↗
WithdrawnPhase not applicable NCT05539950
Sponsor: Taipei Medical University Shuang Ho Hospital (Academic / non-profit / other)
Intervention(s): Cardiopulmonary Rehabilitation
Start: Oct 2022  |  Primary completion: Oct 2024
Record last updated: Mar 2025

In 2022, though the optimized acute medical treatment of COVID-19 was determined, patients often experience the sequelae (also known as post-acute COVID-19 syndrome, the patients might develop cough, breathlessness, fatigue, weakness, impaired activities of daily livings etc.). Until now, there is no consensus for post-acute COVID-19 syndrome management.

View on ClinicalTrials.gov ↗
WithdrawnEarly Phase 1 NCT05371288
Sponsor: University of California, Irvine (Academic / non-profit / other)
Intervention(s): N-Acetylcysteine (NAC)
Start: Jun 2025  |  Primary completion: Sep 2025
Record last updated: Nov 2024

The purpose of this research study is to assess if glutathione, along with NAC (N-acetyl cysteine) and Alpha lipoic acid (ALA), can help reverse some of the COVID long-haul symptoms.Subjects will be randomized in to one of two groups.

View on ClinicalTrials.gov ↗
WithdrawnPhase not applicable NCT06065033
Sponsor: University of Virginia (Academic / non-profit / other)
Intervention(s): Exercise
Start: Sep 2023  |  Primary completion: Mar 2024
Record last updated: May 2024

The COVID-19 pandemic severely impacted the medical system both directly but also through incomplete recovery from the virus in the form of post-acute sequelae of COVID-19 (PASC). PASC affects at least 9.6 million individuals as of May 2022 and continues to affect many more. PASC is a multisystem disorder often presenting with mental fog, dyspnea on exertion, and fatigue among other symptoms.

View on ClinicalTrials.gov ↗
WithdrawnPhase not applicable NCT05543590
Sponsor: Hôpital Européen Marseille (Academic / non-profit / other)
Intervention(s): Plasmapheresis, Blood Collection, Stool Samples, Pet Scan, Cycle Ergometer Stress Test, Medical Consultations
Start: Feb 2023  |  Primary completion: Feb 2025
Record last updated: Aug 2023

Many patients infected with SARS-Cov-2 present in the months following infection with non-specific symptoms such as non-resolving fatigue, cognitive disorders, dyspnea, headaches, myalgias, sleep disorders, anosmia/ ageusia and post exertion malaise. The persistence of these symptoms is called "post covid syndrome" or "long Covid".

View on ClinicalTrials.gov ↗
WithdrawnPhase not applicable NCT05589272
Sponsor: University of Minnesota (Academic / non-profit / other)
Intervention(s): Active Tdcs
Start: Feb 2023  |  Primary completion: Sep 2023
Record last updated: Mar 2023

The overarching goals of this study are to employ cognitive testing to understand how transcranial direct current stimulation (tDCS), when used concurrently with cognitive training tasks, can affect cognitive impairment symptoms in individuals with long COVID, or post-acute sequelae SARS-CoV-2 infection (PASC), and to examine variability in response between active and sham tDCS treatment groups.

View on ClinicalTrials.gov ↗
WithdrawnPhase not applicable NCT04958161
Sponsor: Wake Forest University Health Sciences (Academic / non-profit / other)
Intervention(s): Exercise Therapy
Start: Jan 2022  |  Primary completion: Dec 2022
Record last updated: Feb 2022

Individuals who had COVID-19 and are thought to have recovered from the disease often experience long-term symptoms such as fatigue, extreme tiredness and shortness of breath, a condition referred to as Long COVID. Previous studies have shown that regular exercise is beneficial for individuals suffering similar symptoms as a result of other diseases such as Chronic Fatigue Syndrome.

View on ClinicalTrials.gov ↗

Unknown status (57)

Unknown statusPhase not applicable NCT06348186
Sponsor: University of the State of Santa Catarina (Academic / non-profit / other)
Intervention(s): Guidebook, Guidebook And Myofascial Reorganization® (Rmf).
Start: Feb 2024  |  Primary completion: Apr 2024  |  Enrollment: 30 (estimated)
Record last updated: Nov 2024

According to the World Health Organization (WHO), as of mid-September 2022, more than 21 million Brazilians have recovered from COVID-19. However, post-infection symptoms continue to appear months after the end of the acute infection, a syndrome called long COVID. Therefore, the aim of this study is to investigate the responses of fascia-focused manual therapy in participants with long COVID.

View on ClinicalTrials.gov ↗
Unknown statusPhase 2 NCT04482595
Sponsor: Humanetics Corporation (Industry)
Intervention(s): Bio 300 Oral Suspension
Start: Nov 2020  |  Primary completion: Jul 2024  |  Enrollment: 50 (estimated)
Record last updated: Oct 2024

This is a randomized, double-blinded, placebo-controlled, two-arm study to evaluate the safety and efficacy of BIO 300 Oral Suspension (BIO 300) as a therapy to improve lung function in patients that were hospitalized for severe COVID-19-related illness and continue to experience post-acute respiratory complications associated with Long-COVID after discharge.

View on ClinicalTrials.gov ↗
Unknown statusPhase not applicable NCT06379672
Sponsor: Chengdu Sport University (Academic / non-profit / other)
Intervention(s): Resonance Breathing
Start: Aug 2024  |  Primary completion: Sep 2024  |  Enrollment: 70 (estimated)
Record last updated: Jul 2024

An investigation of the efficacy of resonance breathing training in the rehabilitation of patients with Long covid-related myocardial injury.

View on ClinicalTrials.gov ↗
Unknown statusPhase 1 NCT06492798
Sponsor: Changhai Hospital (Academic / non-profit / other)
Intervention(s): Umbilical Cord Mesenchymal Stem Cell
Start: Sep 2023  |  Primary completion: Jul 2025  |  Enrollment: 76 (estimated)
Record last updated: Jul 2024

The goal of this clinical trial is to evaluate the effectiveness and safety of mesenchymal stem cell therapy in long-COVID patients. The main questions it aims to answer include: * whether umbilical cord mesenchymal stem cell therapy does benefit long-COVID patients * whether umbilical cord mesenchymal stem cell therapy is safe for long-COVID patients.

View on ClinicalTrials.gov ↗
Unknown statusPhase not applicable NCT05019963
Sponsor: University of Ottawa (Academic / non-profit / other)
Intervention(s): Nexj Connected Wellness
Start: May 2022  |  Primary completion: Aug 2024  |  Enrollment: 106 (actual)
Record last updated: Jul 2024

In March 2020, the World Health Organization (WHO) declared the novel coronavirus (COVID-19) a global pandemic. Ontario has confirmed more than 547,000 cases of COVID-19 since testing began. For many of these patients, symptoms resolve within 4 weeks of onset.

View on ClinicalTrials.gov ↗
Unknown statusPhase not applicable NCT05731570
Sponsor: University College, London (Academic / non-profit / other)
Intervention(s): Cognitive Rehabilitation
Start: Feb 2023  |  Primary completion: Jul 2024  |  Enrollment: 78 (actual)
Record last updated: Jun 2024

Cognitive impairment is increasingly recognised as a major component of long Covid, and is estimated to be present in 25-75% of affected individuals. This impairment impacts quality of life and the loss of functional ability has major consequences for affected people, their families and the wider economy given people's difficulty in returning to work.

View on ClinicalTrials.gov ↗
Unknown statusPhase not applicable NCT06456502
Sponsor: Universidad Rey Juan Carlos (Academic / non-profit / other)
Intervention(s): Non-Invasive Neuromodulation
Start: Jun 2024  |  Primary completion: Jun 2026  |  Enrollment: 44 (estimated)
Record last updated: Jun 2024

Sleep quality and duration are critical to cognitive, emotional and physical well-being, and poor sleep quality has been associated with an increased risk of cognitive, psychological and cardiometabolic disorders. Several important physiological activities occur during sleep including a reduction in heart rate and blood pressure. In addition, sleep exerts important modulatory effects on hormone release.

View on ClinicalTrials.gov ↗
Unknown statusPhase not applicable NCT06085911
Sponsor: University Hospital of North Norway (Academic / non-profit / other)
Intervention(s): One Day Course, Individual Follow-Ups
Start: Nov 2023  |  Primary completion: Feb 2025  |  Enrollment: 60 (estimated)
Record last updated: Jun 2024

The Coronavirus 2019 (COVID-19) pandemic has resulted in at least four million infections in Norway. The vast majority of cases are diagnosed and followed up in the community, but some with extensive symptoms and large degree of reduced function are referred to regional Covid-clinics. In total this patient group is placing an enormous burden on the already over stretched health care services.

View on ClinicalTrials.gov ↗
Unknown statusPhase not applicable NCT06423495
Sponsor: Gaffree & Guinle Universitary Hospital (Academic / non-profit / other)
Intervention(s): Low-Intensity Laser Treatment
Start: Jun 2022  |  Primary completion: Dec 2023  |  Enrollment: 30 (estimated)
Record last updated: May 2024

On January 30, 2020, the WHO (World Health Organization) declared the new coronavirus pandemic as the sixth public health emergency of international concern. In February 2020, the virus was designated by the Coronavirus Study Group of the International Committee on Virus Taxonomy as severe acute respiratory syndrome coronavirus 2.

View on ClinicalTrials.gov ↗
Unknown statusPhase not applicable NCT06404411
Sponsor: Chengdu Sport University (Academic / non-profit / other)
Intervention(s): Assigned Interventions, Conventional Rehabilitation
Start: Jun 2024  |  Primary completion: Jun 2025  |  Enrollment: 40 (estimated)
Record last updated: May 2024

A study of the efficacy of aerobic exercise based on cardiopulmonary exercise test in the rehabilitation of patients with COVID-19-related myocardial injury.

View on ClinicalTrials.gov ↗
Unknown statusPhase not applicable NCT05890508
Sponsor: Hong Kong Baptist University (Academic / non-profit / other)
Intervention(s): Acupuncture
Start: Mar 2024  |  Primary completion: Jan 2026  |  Enrollment: 150 (estimated)
Record last updated: May 2024

In this study, a 16-week randomized, sham-controlled, double-blinded clinical trial will be conducted to to investigate the efficacy and safety of electro-acupuncture compared to sham acupuncture for treatment of long covid neuropsychiatric symptoms.

View on ClinicalTrials.gov ↗
Unknown statusPhase not applicable NCT06391970
Sponsor: Luxembourg Institute of Health (Other government)
Intervention(s): Cognitive Screening
Start: Apr 2023  |  Primary completion: Aug 2024  |  Enrollment: 300 (estimated)
Record last updated: Apr 2024

The persistence of the COVID-19 disease symptoms, such as extreme fatigue, shortness of breath, cardiovascular complications, depression and anxiety, pain, brain fog, loss of taste/smell, headaches as well as loss of memory has been evoked in many studies. This project aims at approaching the persistent symptomatology on cognition, more than 1 year after the infection.

View on ClinicalTrials.gov ↗
Unknown statusPhase 2 NCT06074848
Sponsor: Universidade Federal de Pernambuco (Academic / non-profit / other)
Intervention(s): Transcranial Direct Current Stimulation, Motor Training, Cognitive Training
Start: Aug 2023  |  Primary completion: Jul 2024  |  Enrollment: 48 (estimated)
Record last updated: Apr 2024

Different physical and mental morbidities such as pain, fatigue, depressed mood and cognitive impairment can be triggered by coronavirus infection. Transcranial direct current stimulation (tDCS), an easy-to-apply, non-pharmacological and safe technique, has been used to attenuate these symptoms caused by other diseases, and, therefore, it is expected that it can also attenuate them when generated by COVID-19.

View on ClinicalTrials.gov ↗
Unknown statusPhase not applicable NCT06374446
Sponsor: Istinye University (Academic / non-profit / other)
Intervention(s): Classical Treatment, Virtual Reality Combined With Classical Treatment, Virtual Reality
Start: Apr 2024  |  Primary completion: Jun 2024  |  Enrollment: 56 (estimated)
Record last updated: Apr 2024

SARS-CoV-2 was first detected in Wuhan, Hubei Province, China, in late 2019. It is a highly contagious virus that has been reported to occur in humans and is said to cause pneumonia. Covid-19 infection is transmitted through droplets during coughing and sneezing and through contact with the mouth, nose or eyes after contaminated hands.

View on ClinicalTrials.gov ↗
Unknown statusPhase not applicable NCT06348212
Sponsor: Taipei Veterans General Hospital, Taiwan (Other government)
Intervention(s): Lactobacillus Paracasei Ps23, Microcrystalline Cellulose
Start: Apr 2024  |  Primary completion: Aug 2025  |  Enrollment: 60 (estimated)
Record last updated: Apr 2024

The goal of this clinical trial is to test whether the intervention of probiotics supplement can improve symptoms of long covid syndrome. Participants will be given probiotics or placebo capsules for two month. Symptom questionnaires, cognitive function, eeg and fecal sample are recorded/collected before and after the supplement.

View on ClinicalTrials.gov ↗
Unknown statusPhase not applicable NCT06255600
Sponsor: Federal University of Paraíba (Academic / non-profit / other)
Intervention(s): High Definition-Transcranial Direct Current Stimulation, Chlorella Pyrenoidosa
Start: Aug 2021  |  Primary completion: Jun 2024  |  Enrollment: 60 (estimated)
Record last updated: Mar 2024

Recent investigations have shown that of the patients who were affected by SARCov2 have remained with persistent symptoms in a high proportion.

View on ClinicalTrials.gov ↗
Unknown statusPhase 3 NCT06147050
Sponsor: Purpose Life Sciences (Academic / non-profit / other)
Intervention(s): Metformin
Start: Apr 2024  |  Primary completion: Oct 2024  |  Enrollment: 16 (estimated)
Record last updated: Mar 2024

Long Covid is a multisystem condition comprising often severe symptoms that follow a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Long COVID often manifests as fatigue and neurocognitive impairment (also referred to as 'brain fog').

View on ClinicalTrials.gov ↗
Unknown statusPhase 3 NCT06267300
Sponsor: Erasmus Medical Center (Academic / non-profit / other)
Start: Oct 2024  |  Primary completion: Oct 2025  |  Enrollment: 120 (estimated)
Record last updated: Feb 2024

The goal of this clinical try is to investigate the effect of hyperbaric oxygen therapy (HBOT) on symptoms, quality of life and absence of work through sickness in patients with post-COVID on short- and mid-term, as well as to identify biochemical mechanisms of action.

View on ClinicalTrials.gov ↗
Unknown statusPhase not applicable NCT06231225
Sponsor: National Taipei University of Nursing and Health Sciences (Academic / non-profit / other)
Intervention(s): Incentive Spirometer Respiratory Training
Start: Jul 2024  |  Primary completion: Jun 2025  |  Enrollment: 100 (estimated)
Record last updated: Jan 2024

The COVID-19 pandemic has emerged as the most significant public health crisis of the 21st century. As of the end of January 2023, global confirmed cases have exceeded 670 million, with a domestic cumulative total of 10.24 million cases, including occurrences of reinfection. Beyond acute symptoms following infection, patients and society face the challenge of long-term complications associated with COVID-19.

View on ClinicalTrials.gov ↗
Unknown statusPhase 3 NCT06166030
Sponsor: Federal University of São Paulo (Academic / non-profit / other)
Intervention(s): Nutritional Blend (Immunerecov).
Start: Dec 2023  |  Primary completion: Dec 2024  |  Enrollment: 58 (estimated)
Record last updated: Dec 2023

COVID-19 left consequences in different organs from months to years requiring different types of rehabilitation. In fact, a severe loss in the lung function, and in the respiratory and peripheral muscle strength is commonly observed in post-COVID-19 patients.

View on ClinicalTrials.gov ↗
Unknown statusPhase not applicable NCT06159296
Sponsor: Oxford Brookes University (Academic / non-profit / other)
Intervention(s): Hydroxy Gas
Start: Sep 2023  |  Primary completion: May 2024  |  Enrollment: 25 (estimated)
Record last updated: Dec 2023

The goal of this clinical trial is to see if several weeks of self-administered, home-based, treatment involving breathing hydroxy gas (a mixture of hydrogen and oxygen) for at least 2 hours a day for 3 weeks, will relieve symptoms in patients suffering from Long COVID.

View on ClinicalTrials.gov ↗
Unknown statusPhase 1 NCT06156241
Sponsor: Charles Cox (Academic / non-profit / other)
Intervention(s): Stem Cell
Start: Jan 2024  |  Primary completion: Dec 2025  |  Enrollment: 12 (estimated)
Record last updated: Dec 2023

The purpose of this research study is to test the safety and benefit of a human cord blood derived stem cell infusion as a treatment for individuals with post COVID-19 neurological problems. Participants in the study will have 6 clinic visits over a 12 to 14 mo. period with each visit lasting 2 to 6 hours. Participants will receive 1 stem cell infusion at study visit #3.

View on ClinicalTrials.gov ↗
Unknown statusPhase not applicable NCT06091358
Sponsor: University of Bath (Academic / non-profit / other)
Intervention(s): Pro2
Start: Oct 2023  |  Primary completion: Mar 2024  |  Enrollment: 16 (estimated)
Record last updated: Nov 2023

This pilot investigation will recruit people with Long COVID to participate in a 4 week individualized inspiratory muscle training intervention with pre and post spirometry testing and additional functional outcomes to assess the effectiveness of the intervention.

View on ClinicalTrials.gov ↗
Unknown statusPhase not applicable NCT05668039
Sponsor: Sheba Medical Center (Other government)
Start: Apr 2023  |  Primary completion: Apr 2024  |  Enrollment: 32 (estimated)
Record last updated: Nov 2023

The goal of this double blind, outcome-assessor blind, randomized controlled trial, is to compare the effectiveness of external encounter counterpulsation (EECP) versus sham procedure in participants with long COVID-19 fatigue.

View on ClinicalTrials.gov ↗
Unknown statusPhase 4 NCT05481177
Sponsor: Uniformed Services University of the Health Sciences (US federal agency)
Intervention(s): Ivabradine
Start: Jun 2023  |  Primary completion: Sep 2024  |  Enrollment: 250 (estimated)
Record last updated: Nov 2023

The purpose of the study is three-fold. The primary aim is to identify the proportion of Long-Haul COVID (LHC) and non-LHC volunteers with relevant symptoms actually have postural orthostatic tachycardia syndrome (POTS). The second is to determine benefit of ivabradine treatment.

View on ClinicalTrials.gov ↗
Unknown statusPhase not applicable NCT06142240
Sponsor: Facultat de ciencies de la Salut Universitat Ramon Llull (Academic / non-profit / other)
Intervention(s): Exercise Programe
Start: Jun 2023  |  Primary completion: Apr 2025  |  Enrollment: 40 (estimated)
Record last updated: Nov 2023

Symptoms of long-standing sequelae and complications of COVID-19, termed Long COVID19 or persistent COVID, have been reported worldwide.

View on ClinicalTrials.gov ↗
Unknown statusPhase not applicable NCT05556733
Sponsor: Chinese University of Hong Kong (Academic / non-profit / other)
Intervention(s): Faecal Microbiota Transplantation
Start: Sep 2022  |  Primary completion: Sep 2023  |  Enrollment: 60 (estimated)
Record last updated: Oct 2023

In recovered COVID-19 patients, emerging global data have reported the presence of long COVID, that is, at least one symptom that an alternative diagnosis cannot explain has been persistent for four or more weeks after the initial infection. We demonstrated previously that almost 80% of recovered COVID-19 patients in Hong Kong suffer from Long COVID for more than 6 months, affecting multiple body systems.

View on ClinicalTrials.gov ↗
Unknown statusPhase 2 NCT06095258
Sponsor: Chinese University of Hong Kong (Academic / non-profit / other)
Intervention(s): Traditional Chinese Medicine Treatment, Western Medicine Treatment
Start: Dec 2023  |  Primary completion: Nov 2025  |  Enrollment: 162 (estimated)
Record last updated: Oct 2023

This is a multi-center, outcome assessor-blinded, practical randomized controlled trial, aiming to compare the actual clinical effectiveness of individualized traditional Chinese medicine and conventional Western medicine in the treatment of long COVID.

View on ClinicalTrials.gov ↗
Unknown statusPhase not applicable NCT06042777
Sponsor: The Hong Kong Polytechnic University (Academic / non-profit / other)
Intervention(s): Acupuncture And Tcm-Based Lifestyle Management
Start: Sep 2023  |  Primary completion: May 2024  |  Enrollment: 100 (estimated)
Record last updated: Sep 2023

Cognitive impairment is one of the commonly reported Long COVID symptoms, mainly in terms of memory, attention, and executive function. The cognitive symptoms of Long COVID are similar to "brain fog" or "chemo brain", manifested as low energy, disorientation, difficulties in attention and communication which are common conditions in cancer patients after chemotherapy.

View on ClinicalTrials.gov ↗
Unknown statusPhase not applicable NCT05705154
Sponsor: Royal Brompton & Harefield NHS Foundation Trust (Academic / non-profit / other)
Intervention(s): Psychology Interventions
Start: Apr 2023  |  Primary completion: Mar 2024  |  Enrollment: 40 (estimated)
Record last updated: Sep 2023

Recruitment target: Phase I: Co-design of intervention: 5 to 15 CYP aged between 12-18 years of age referred to the pan-London long COVID MDT. Phase II: Randomised pilot: 40 patients (12-18 years) will be recruited from a potential pool of 214 patients referred to the pan-London long COVID MDT.

View on ClinicalTrials.gov ↗
Unknown statusPhase not applicable NCT05040893
Sponsor: University of Calgary (Academic / non-profit / other)
Intervention(s): Physiotherapy
Start: Mar 2022  |  Primary completion: Aug 2023  |  Enrollment: 15 (actual)
Record last updated: Aug 2023

The purpose of this study is to determine the benefits and feasibility of physiotherapy in the recovery of ongoing symptoms after COVID-19 illness. Long COVID Syndrome (Long COVID) is defined by persistent symptoms (including breathlessness, chest pain and fatigue) after COVID-19 illness that continue for more than 12 weeks and cannot be explained by another diagnosis.

View on ClinicalTrials.gov ↗
Unknown statusPhase not applicable NCT05975034
Sponsor: Sheffield Hallam University (Academic / non-profit / other)
Intervention(s): Probiotic
Start: Jun 2023  |  Primary completion: Dec 2023  |  Enrollment: 240 (estimated)
Record last updated: Aug 2023

This study is a double-blinded randomised trial to assess the efficacy of a probiotic supplement in alleviating symptoms in people with Long COVID.

View on ClinicalTrials.gov ↗
Unknown statusPhase 1 NCT05947617
Sponsor: Neobiosis, LLC (Industry)
Intervention(s): Vix001
Start: Oct 2023  |  Primary completion: Apr 2025  |  Enrollment: 9 (estimated)
Record last updated: Jul 2023

The study, identified as VIX001-PACS-01, is a Phase 1, open-label, dose-escalation trial evaluating the safety, tolerability, preliminary efficacy, and dose effect of VIX001, an amniotic fluid product, in patients with Post-Acute COVID-19 Syndrome (PACS) and cognitive impairment.

View on ClinicalTrials.gov ↗
Unknown statusPhase not applicable NCT05932797
Sponsor: Universidad de Magallanes (Academic / non-profit / other)
Intervention(s): Multimodal Intervention In Long Covid19
Start: May 2023  |  Primary completion: Nov 2024  |  Enrollment: 60 (estimated)
Record last updated: Jul 2023

Due to the COVID-19 pandemic, the world has seen the need to identify groups of patients who experience various effects in the medium and long term after recovering from the initial illness. These medium- and long-term effects are collectively known as the post-COVID-19 condition, Long-COVID, or prolonged COVID.

View on ClinicalTrials.gov ↗
Unknown statusPhase not applicable NCT05815693
Sponsor: Azienda Socio Sanitaria Territoriale di Lecco (Academic / non-profit / other)
Intervention(s): Mindfulness-Based Stress Reduction
Start: Apr 2023  |  Primary completion: Nov 2023  |  Enrollment: 140 (estimated)
Record last updated: Jun 2023

The consequences of the Intensive Care Unit and the Covid-19 disease are still uncertain. However, many studies are bringing out often psychological and dramatic consequences for many COVID-survivor patients.

View on ClinicalTrials.gov ↗
Unknown statusPhase 2 NCT05684952
Sponsor: Hong Kong Baptist University (Academic / non-profit / other)
Intervention(s): Shenlingcao Oral Liquid
Start: May 2023  |  Primary completion: Jan 2024  |  Enrollment: 152 (estimated)
Record last updated: Jun 2023

This is a randomized, double-blinded, placebo-controlled clinical trial to determine the efficacy and safety of a Chinese herbal medicine (Shenlingcao oral liquid) for treating long COVID associated fatigue.

View on ClinicalTrials.gov ↗
Unknown statusPhase not applicable NCT05918965
Sponsor: Medical University of Vienna (Academic / non-profit / other)
Intervention(s): Transcutaneous Electrical Vagal Neurostimulation
Start: Mar 2023  |  Primary completion: Mar 2025  |  Enrollment: 45 (estimated)
Record last updated: Jun 2023

The aim of the present pilot study is to investigate the acceptance, feasibility and implementation of the vagus nerv stimulation in Long COVID patients. Additionally, the effects on parameters of the autonomic nervous system as well as on symptoms of Long COVID will be described in a pre/post comparison.

View on ClinicalTrials.gov ↗
Unknown statusPhase not applicable NCT05780450
Sponsor: Fundación Universidad Católica de Valencia San Vicente Mártir (Academic / non-profit / other)
Intervention(s): Transcranial Direct Current Therapy
Start: Apr 2023  |  Primary completion: Jul 2023  |  Enrollment: 27 (estimated)
Record last updated: Jun 2023

This study aims to verify the efficacy / effectiveness of treatment with transcranial direct therapy (TDCS) in patients with Persistent Covid who present headaches, migraines and chronic pain, such as arthralgias and myalgias.

View on ClinicalTrials.gov ↗
Unknown statusPhase 1 NCT05669261
Sponsor: American CryoStem Corporation (Industry)
Intervention(s): Adipose Tissue Harvest, Atcell
Start: Aug 2023  |  Primary completion: Dec 2023  |  Enrollment: 20 (estimated)
Record last updated: Jun 2023

The project is described as a Phase 1 Clinical Safety Study intended to provide preliminary assessments of the safety, tolerability, and secondarily to be vigilant for signals of amelioration of symptoms associated with Post-Acute Sequelae of SARS-CoV-2 infection.

View on ClinicalTrials.gov ↗
Unknown statusPhase not applicable NCT05681455
Sponsor: Universidad Rey Juan Carlos (Academic / non-profit / other)
Intervention(s): Neuromodulation Nesa Nxsignal® Device
Start: Jun 2023  |  Primary completion: Jun 2023  |  Enrollment: 24 (estimated)
Record last updated: Jun 2023

To evaluate pressure pain thresholds, fatigue scales, quality of life and sleep quality, in women with Persistent Covid (PC), pre- and post-treatment using electrotherapy and in a placebo group of PC patients. Relevance: This trial can be a tool for patients affected by CP who present pain and fatigue problems, insomnia or signs of imbalance of their Autonomic Nervous System.

View on ClinicalTrials.gov ↗
Unknown statusPhase not applicable NCT05874089
Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico (Academic / non-profit / other)
Intervention(s): Vsl#3®
Start: Nov 2022  |  Primary completion: Sep 2023  |  Enrollment: 96 (estimated)
Record last updated: May 2023

This study aims to evaluate the effectiveness of VSL#3® in reducing Fatigue and other symptoms in Long Covid Syndrome compared to placebo.

View on ClinicalTrials.gov ↗
Unknown statusPhase not applicable NCT05855356
Sponsor: Evangelismos Hospital (Academic / non-profit / other)
Intervention(s): Rehabilitation, Standard Of Care
Start: Feb 2023  |  Primary completion: Dec 2023  |  Enrollment: 50 (estimated)
Record last updated: May 2023

Dysautonomia in post-covid-19 condition appears to affect a significant number of patients, with reports raising the incidence up to 61%, having an overlap with myalgic encephalomyelitis/ chronic fatigue syndrome. Quality of life and daily function is significantly impacted and conservative management interventions, despite the lack of high quality evidence up to now, are needed to ameliorate disability.

View on ClinicalTrials.gov ↗
Unknown statusPhase not applicable NCT05851846
Sponsor: Miami VA Healthcare System (US federal agency)
Intervention(s): Amygdala Insula Retraining
Start: May 2023  |  Primary completion: May 2024  |  Enrollment: 130 (estimated)
Record last updated: May 2023

The goal of the study is to compare a mind body intervention against usual care in patients with fatigue with long COVID. Our research questions include 1. Is the mind body intervention additive to usual care in long COVID 2.

View on ClinicalTrials.gov ↗
Unknown statusPhase not applicable NCT05012826
Sponsor: Centro Universitário Augusto Motta (Academic / non-profit / other)
Intervention(s): Osteopathic Manipulative Treatment In Addition To Physiotherapy, Physiotherapy
Start: Sep 2021  |  Primary completion: Jun 2023  |  Enrollment: 104 (estimated)
Record last updated: May 2023

Fatigue is among the most common symptoms of the long-term effects of coronavirus (long COVID). This study aims to compare the effectiveness of osteopathic manipulative treatment (OMT) combined with physiotherapy treatment (PT) compared to PT alone on fatigue and functional limitations after two months post randomization in adults with long COVID.

View on ClinicalTrials.gov ↗
Unknown statusPhase not applicable NCT05817032
Sponsor: Universitas Indonesia (Academic / non-profit / other)
Intervention(s): Telerehabilitation, Standard Rehabilitation Care
Start: May 2023  |  Primary completion: Oct 2023  |  Enrollment: 22 (estimated)
Record last updated: Apr 2023

The goal of this clinical trial is to test the efficacy of telerehabilitation practice in Long COVID-19 patients. The main question\[s\] it aims to answer are whether telerehabilitation practice in Long COVID-19 patients help to reduce stress oxidative, reduce inflammation, improve functional capacity and improve quality of life.

View on ClinicalTrials.gov ↗
Unknown statusEarly Phase 1 NCT05808400
Sponsor: Huazhong University of Science and Technology (Academic / non-profit / other)
Intervention(s): Msc-Derived Exosomes
Start: Feb 2023  |  Primary completion: Feb 2024  |  Enrollment: 80 (estimated)
Record last updated: Apr 2023

This clinical trial aims to evaluate the safety and effectiveness of umbilical cord mesenchymal stem cell (UCMSC)-derived extracellular vesicle nebulization inhalation therapy for the treatment of chronic cough after COVID-19 infection. The main objective is to assess whether UCMSC-derived exosome nebulization inhalation therapy alleviates chronic cough after COVID-19.

View on ClinicalTrials.gov ↗
Unknown statusPhase not applicable NCT05616806
Sponsor: Rhode Island Hospital (Academic / non-profit / other)
Intervention(s): Iendure
Start: Jul 2023  |  Primary completion: Jul 2024  |  Enrollment: 10 (estimated)
Record last updated: Apr 2023

The current study seeks to pilot test the iENDURE (Enhancing Distress tolerance to Uplift motivation in Recovery) intervention among 10 participants with Long COVID (Coronavirus Disease) symptoms. Following informed consent procedures, participants will complete a brief baseline assessment of self-report measures. Participants will then engage in the iENDURE intervention (described below) for 4 weeks.

View on ClinicalTrials.gov ↗
Unknown statusPhase not applicable NCT05725538
Sponsor: University of Cadiz (Academic / non-profit / other)
Intervention(s): Covidreapp Group
Start: Mar 2023  |  Primary completion: Mar 2024  |  Enrollment: 100 (estimated)
Record last updated: Feb 2023

Post-Acute Syndrome COVID-19 is a disease resulting from infection by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is estimated that between 10 and 35% of infected persons suffer symptoms afterwards, and in hospitalized patients it can reach 85%. These sequelae have individual, social and economic repercussions, so effective rehabilitation alternatives are necessary.

View on ClinicalTrials.gov ↗
Unknown statusPhase 2 NCT05706454
Sponsor: KARE Biosciences (Industry)
Intervention(s): Ramatroban
Start: Nov 2022  |  Primary completion: Jul 2024  |  Enrollment: 324 (estimated)
Record last updated: Jan 2023

Phase II/Phase III study to evaluate the safety and efficacy of Ramatroban 75 mg tablet against Placebo in subjects hospitalized for pneumonia due to SARS-CoV-2 infection. Approximately 324 eligible subjects will be randomized in a 1:1 ratio to one of the two treatment groups. Group I: Ramatroban 75 mg tablet + Standard of care; Group II: Placebo + Standard of care.

View on ClinicalTrials.gov ↗
Unknown statusPhase not applicable NCT05289154
Sponsor: Charite University, Berlin, Germany (Academic / non-profit / other)
Intervention(s): Self- Applied Acupressure Plus Qigong Course Plus Advice Literature, Advice Literature With Naturopathy
Start: Jun 2022  |  Primary completion: Sep 2023  |  Enrollment: 200 (estimated)
Record last updated: Jan 2023

International observational studies confirm the high incidence of post-infectious residual syndrome after infection with severe acute respiratory syndrome corona virus 2 (SARS-COV2), which can occur in 10-15% of all infected persons, regardless of the severity of the acute infection.

View on ClinicalTrials.gov ↗
Unknown statusPhase not applicable NCT05629884
Sponsor: Fundacin Biomedica Galicia Sur (Academic / non-profit / other)
Intervention(s): Coperia-Rehab
Start: Dec 2022  |  Primary completion: Nov 2023  |  Enrollment: 56 (estimated)
Record last updated: Nov 2022

The pandemic caused by SARS-CoV-2 infection has resulted, in addition to the well-known acute symptoms, in the emergence of a plethora of persistent, diffuse and heterogeneous symptoms such as fatigue, shortness of breath and cognitive dysfunction among others, that have come to be called persistent COVID.

View on ClinicalTrials.gov ↗
Unknown statusPhase not applicable NCT05629793
Sponsor: Fundacin Biomedica Galicia Sur (Academic / non-profit / other)
Intervention(s): Experimental Tests
Start: Dec 2022  |  Primary completion: Nov 2023  |  Enrollment: 136 (estimated)
Record last updated: Nov 2022

The pandemic caused by SARS-CoV-2 infection has resulted, in addition to the well-known acute symptoms, in the emergence of persistent, diffuse and heterogeneous symptoms referred to as persistent COVID. Common symptoms include fatigue, shortness of breath, and cognitive dysfunction, among others, and result in an impact on daily functioning.

View on ClinicalTrials.gov ↗
Unknown statusPhase not applicable NCT04742946
Sponsor: Universidad de Granada (Academic / non-profit / other)
Intervention(s): Digital Physiotherapy Practice
Start: Dec 2021  |  Primary completion: Dec 2022  |  Enrollment: 27 (estimated)
Record last updated: Nov 2022

The COVID-19 can cause important sequels in the respiratory system by bilateral pneumonia and frequently presents loss of strength, dyspnea, polyneuropathies and multi-organic affectation. Long COVID-19 has been defined as the condition occurring in individuals with a history of probable or confirmed SARS-CoV-2 infection, with related symptoms lasting at least 2 months and not explainable by an alternative diagnosis.

View on ClinicalTrials.gov ↗
Unknown statusPhase not applicable NCT05228665
Sponsor: University of Leeds (Academic / non-profit / other)
Intervention(s): Heart Rate Variability Biofeedback
Start: Jan 2022  |  Primary completion: Dec 2023  |  Enrollment: 30 (estimated)
Record last updated: Oct 2022

Long COVID is a common but highly debilitating illness which develops after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or COVID-19). It is thought to affect as many as 1 in 7 people following COVID-19 infection. It can produce a vast array of symptoms including fatigue, breathlessness, fast heart rate, blood pressure disturbance, temperature disturbance, and dry mouth.

View on ClinicalTrials.gov ↗
Unknown statusPhase 1 NCT05582603
Sponsor: Universidad Antonio de Nebrija (Academic / non-profit / other)
Intervention(s): Cct Long Covid
Start: Oct 2022  |  Primary completion: Nov 2022  |  Enrollment: 20 (estimated)
Record last updated: Oct 2022

The goal of this Phase I/II clinical trial is to assess the safety and maximum tolerated training time of a self-administered computerized cognitive training (CCT) in individuals with cognitive dysfunction as a consequence of COVID-19 infection.

View on ClinicalTrials.gov ↗
Unknown statusPhase not applicable NCT05543408
Sponsor: Universidad San Jorge (Academic / non-profit / other)
Intervention(s): Exercise
Start: May 2022  |  Primary completion: Aug 2022  |  Enrollment: 40 (estimated)
Record last updated: Sep 2022

This is a randomized controlled trial of the efficacy of an individualized, progressive, exercise program (strength, cardiovascular, and breathing exercises) in recovering people from the post-COVID-19 syndrome (i.e., patients who present symptoms \>12 weeks once the acute phase of the disease is over).

View on ClinicalTrials.gov ↗
Unknown statusPhase not applicable NCT05534997
Sponsor: Cairo University (Academic / non-profit / other)
Intervention(s): Intensive Combined Rehabilitation Therapy
Start: Oct 2022  |  Primary completion: Sep 2023  |  Enrollment: 60 (estimated)
Record last updated: Sep 2022

The aim of this study is to investigate the effect of intensive combined rehabilitation therapy in form of Graded Exercise Therapy (GET) , Cognitive Behavioral Therapy (CBT) to treat patients with post COVID19 chronic fatigue syndrome .

View on ClinicalTrials.gov ↗

Frequently asked questions

Does the Open Source Medicine Foundation run these trials?

No. OSMF does not sponsor, run or recruit for any trial on this page. We compile public registry entries from ClinicalTrials.gov so patients and clinicians can find them in one place. For questions about a specific study, contact the sponsor or study team listed on its ClinicalTrials.gov record.

What do the trial phases mean?

Early Phase 1 / Phase 1 studies test safety and dosing in a small group. Phase 2 studies look for a signal of benefit in a larger group and keep checking safety. Phase 3 studies are large confirmatory trials designed to show whether a treatment works well enough for approval. Phase 4 studies follow approved treatments after they reach the market. "Phase not applicable" is used by the registry for behavioural, device, rehabilitation and other non-drug interventions.

Why is a trial I know about missing?

Our search targets interventional studies whose registered conditions map to Long COVID / PASC, ME/CFS or overlapping post-viral syndromes. Observational studies, trials registered only on non-US registries (EU CTR, ISRCTN, ANZCTR, etc.), and trials whose condition terms did not match our mapping are not included. The full ClinicalTrials.gov search is always more complete than any curated index.

What does "terminated" or "withdrawn" mean?

Terminated means the study started but stopped early, for reasons that can include lack of funding, slow recruitment, safety signals or clear futility; the record often states why. Withdrawn means the study was cancelled before enrolling anyone. Suspended means enrolment is paused and may resume.

Get new recruiting trials in your inbox.

We summarise newly registered post-viral trials and notable results on the OSMF Substack.

Subscribe on Substack
Cite this page
Open Source Medicine Foundation. All Long COVID clinical trials on ClinicalTrials.gov (341 trials, updated October 2026). Research Tracker, 07 October 2026. https://research.opensourcemed.info/trials/all-long-covid.html
Underlying dataset (JSON, CC BY 4.0): https://research.opensourcemed.info/data/clinical_trials/clinical_trials_current.json. Source records: ClinicalTrials.gov.

Related: recruiting Long COVID trials · Long COVID research hub · interactive trial finder.